Document and Entity Information
Document and Entity Information | 6 Months Ended |
Jun. 30, 2024 | |
Document and Entity Information | |
Entity Registrant Name | ASTRAZENECA PLC |
Entity Central Index Key | 0000901832 |
Document Type | 6-K |
Document Period End Date | Jun. 30, 2024 |
Amendment Flag | false |
Current Fiscal Year End Date | --12-31 |
Document Fiscal Period Focus | Q2 |
Document Fiscal Year Focus | 2024 |
Condensed consolidated statemen
Condensed consolidated statement of comprehensive income - USD ($) shares in Millions, $ in Millions | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2024 | [1] | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | |
Condensed consolidated statement of comprehensive income | |||||
Total Revenue | $ 12,938 | $ 11,416 | $ 25,617 | $ 22,295 | |
Product Sales | 12,452 | 10,882 | 24,629 | 21,448 | |
Alliance revenue | 482 | 341 | 939 | 627 | |
Collaboration Revenue | 4 | 193 | 49 | 220 | |
Cost of sales | (2,183) | (1,960) | (4,401) | (3,865) | |
Gross profit | 10,755 | 9,456 | 21,216 | 18,430 | |
Distribution expense | (132) | (131) | (267) | (265) | |
Research and development expense | (3,008) | (2,667) | (5,791) | (5,278) | |
Selling, general and administrative expense | (4,929) | (4,986) | (9,424) | (9,045) | |
Other operating income and expense | 60 | 784 | 127 | 1,163 | |
Operating profit | 2,746 | 2,456 | 5,861 | 5,005 | |
Finance income | 100 | 64 | 211 | 141 | |
Finance expense | (443) | (431) | (856) | (795) | |
Share of after tax losses in associates and joint ventures | (6) | (1) | (19) | (1) | |
Profit before tax | 2,397 | 2,088 | 5,197 | 4,350 | |
Taxation | (469) | (268) | (1,089) | (726) | |
Profit for the period | 1,928 | 1,820 | 4,108 | 3,624 | |
Other comprehensive income | |||||
Remeasurement of the defined benefit pension liability | (43) | 17 | 101 | 7 | |
Net gains/(losses) on equity investments measured at fair value through other comprehensive income | 54 | (94) | 89 | (48) | |
Fair value movements related to own credit risk on bonds designated as fair value through profit or loss | 12 | 2 | 12 | 4 | |
Tax on items that will not be reclassified to profit or loss | 12 | (29) | (27) | (5) | |
Total other comprehensive income that will not be reclassified to profit or loss, net of tax | 35 | (104) | 175 | (42) | |
Foreign exchange arising on consolidation | (39) | (209) | (554) | 105 | |
Foreign exchange arising on designated liabilities in net investment hedges | 2 | (94) | (96) | (101) | |
Fair value movements on cash flow hedges | (52) | 33 | (138) | 89 | |
Fair value movements on cash flow hedges transferred to profit and loss | 32 | 4 | 102 | (71) | |
Fair value movements on derivatives designated in net investment hedges | 23 | 24 | 45 | 40 | |
Gains/(costs) of hedging | (1) | (1) | 14 | (1) | |
Tax on items that may be reclassified subsequently to profit or loss | 3 | 38 | 12 | ||
Total other comprehensive income that may be reclassified subsequently to profit or loss, net of tax | (32) | (243) | (589) | 73 | |
Other comprehensive (expense)/income, net of tax | 3 | (347) | (414) | 31 | |
Total comprehensive income for the period | 1,931 | 1,473 | 3,694 | 3,655 | |
Profit attributable to: | |||||
Owners of the Parent | 1,927 | 1,818 | 4,106 | 3,621 | |
Non-controlling interests | 1 | 2 | 2 | 3 | |
Profit for the period | 1,928 | 1,820 | 4,108 | 3,624 | |
Total comprehensive income attributable to: | |||||
Owners of the Parent | 1,930 | 1,471 | 3,692 | 3,652 | |
Non-controlling interests | 1 | 2 | 2 | 3 | |
Total comprehensive income for the period | $ 1,931 | $ 1,473 | $ 3,694 | $ 3,655 | |
Basic earnings per $0.25 Ordinary Share | $ 1.24 | $ 1.17 | $ 2.65 | $ 2.34 | |
Diluted earnings per $0.25 Ordinary Share | $ 1.24 | $ 1.17 | $ 2.63 | $ 2.32 | |
Weighted average number of Ordinary Shares in issue (millions) | 1,550 | 1,550 | 1,549 | 1,549 | |
Diluted weighted average number of Ordinary Shares in issue (millions) | 1,560 | 1,560 | 1,560 | 1,560 | |
[1] The Q2 2024 and Q2 2023 information in respect of the three months ended 30 June 2024 and 30 June 2023 respectively included in the Interim financial statements have not been reviewed by PricewaterhouseCoopers LLP. |
Condensed consolidated statem_2
Condensed consolidated statement of comprehensive income (Parenthetical) - $ / shares | Jun. 30, 2024 | Jun. 30, 2023 |
Condensed consolidated statement of comprehensive income | ||
Par value per ordinary share | $ 0.25 | $ 0.25 |
Condensed consolidated statem_3
Condensed consolidated statement of financial position - USD ($) $ in Millions | Jun. 30, 2024 | [1] | Dec. 31, 2023 | Jun. 30, 2023 |
Non-current assets | ||||
Property, plant and equipment | $ 9,630 | $ 9,402 | $ 8,675 | |
Right-of-use assets | 1,203 | 1,100 | 949 | |
Goodwill | 21,060 | 20,048 | 19,960 | |
Intangible assets | 39,426 | 38,089 | 38,326 | |
Investments in associates and joint ventures | 264 | 147 | 72 | |
Other investments | 1,607 | 1,530 | 1,071 | |
Derivative financial instruments | 217 | 228 | 163 | |
Other receivables | 806 | 803 | 752 | |
Deferred tax assets | 4,734 | 4,718 | 3,736 | |
Total non-current assets | 78,947 | 76,065 | 73,704 | |
Current assets | ||||
Inventories | 5,667 | 5,424 | 5,051 | |
Trade and other receivables | 11,047 | 12,126 | 11,092 | |
Other investments | 160 | 122 | 148 | |
Derivative financial instruments | 28 | 116 | 44 | |
Income tax receivable | 1,575 | 1,426 | 840 | |
Cash and cash equivalents | 6,916 | 5,840 | 5,664 | |
Total current assets | 25,393 | 25,054 | 22,839 | |
Total assets | 104,340 | 101,119 | 96,543 | |
Current liabilities | ||||
Interest-bearing loans and borrowings | (5,067) | (5,129) | (4,556) | |
Lease liabilities | (292) | (271) | (231) | |
Trade and other payables | (20,463) | (22,374) | (19,738) | |
Derivative financial instruments | (51) | (156) | (83) | |
Provisions | (1,168) | (1,028) | (567) | |
Income tax payable | (1,525) | (1,584) | (1,200) | |
Total current liabilities | (28,566) | (30,542) | (26,375) | |
Non-current liabilities | ||||
Interest-bearing loans and borrowings | (27,225) | (22,365) | (24,329) | |
Lease liabilities | (949) | (857) | (722) | |
Derivative financial instruments | (61) | (38) | (68) | |
Deferred tax liabilities | (3,333) | (2,844) | (2,800) | |
Retirement benefit obligations | (1,326) | (1,520) | (1,078) | |
Provisions | (1,074) | (1,127) | (1,357) | |
Other payables | (2,208) | (2,660) | (2,398) | |
Total non-current liabilities | (36,176) | (31,411) | (32,752) | |
Total liabilities | (64,742) | (61,953) | (59,127) | |
Net assets | 39,598 | 39,166 | 37,416 | |
Equity | ||||
Share capital | 388 | 388 | 387 | |
Share premium account | 35,199 | 35,188 | 35,163 | |
Other reserves | 2,078 | 2,065 | 2,076 | |
Retained earnings | 1,847 | 1,502 | (234) | |
Total equity attributable to owners of parent | 39,512 | 39,143 | 37,392 | |
Non-controlling interests | 86 | 23 | 24 | |
Total equity | $ 39,598 | $ 39,166 | $ 37,416 | |
[1] The Condensed consolidated statement of financial position as at 30 June 2024 and 30 June 2023 have been reviewed by PricewaterhouseCoopers LLP. The Condensed consolidated statement of financial position as at 31 December 2023 has been audited by PricewaterhouseCoopers LLP. |
Condensed consolidated statem_4
Condensed consolidated statement of changes in equity - USD ($) $ in Millions | Share Capital | Share Premium account | Other reserves | Retained earnings | Total attributable to owners of the parent | Non-controlling interests | Total | |
Equity at beginning of period at Dec. 31, 2022 | $ 387 | $ 35,155 | $ 2,069 | $ (574) | $ 37,037 | $ 21 | $ 37,058 | |
Profit for the period | 3,621 | 3,621 | 3 | 3,624 | ||||
Other comprehensive income (expense) | 31 | 31 | 31 | |||||
Transfer to other reserves | 7 | (7) | ||||||
Dividends | (3,047) | (3,047) | (3,047) | |||||
Issue of Ordinary Shares | 8 | 8 | 8 | |||||
Share-based payments charge for the period | 274 | 274 | 274 | |||||
Settlement of share plan awards | (532) | (532) | (532) | |||||
Net movement | 8 | 7 | 340 | 355 | 3 | 358 | ||
Equity at end of period at Jun. 30, 2023 | 387 | 35,163 | 2,076 | (234) | 37,392 | 24 | 37,416 | |
Equity at beginning of period at Dec. 31, 2023 | 388 | 35,188 | 2,065 | 1,502 | 39,143 | 23 | 39,166 | |
Profit for the period | 4,106 | 4,106 | 2 | 4,108 | ||||
Other comprehensive income (expense) | (414) | (414) | (414) | |||||
Transfer to other reserves | 13 | (13) | ||||||
Dividends | (3,052) | (3,052) | (3,052) | |||||
Changes in non-controlling interest | 61 | 61 | ||||||
Issue of Ordinary Shares | 11 | 11 | 11 | |||||
Share-based payments charge for the period | 307 | 307 | 307 | |||||
Settlement of share plan awards | (589) | (589) | (589) | |||||
Net movement | 11 | 13 | 345 | 369 | 63 | 432 | ||
Equity at end of period at Jun. 30, 2024 | $ 388 | $ 35,199 | $ 2,078 | $ 1,847 | $ 39,512 | $ 86 | $ 39,598 | [1] |
[1] The Condensed consolidated statement of financial position as at 30 June 2024 and 30 June 2023 have been reviewed by PricewaterhouseCoopers LLP. The Condensed consolidated statement of financial position as at 31 December 2023 has been audited by PricewaterhouseCoopers LLP. |
Condensed consolidated statem_5
Condensed consolidated statement of cash flows - USD ($) $ in Millions | 6 Months Ended | ||
Jun. 30, 2024 | Jun. 30, 2023 | ||
Cash flows from operating activities | |||
Profit before tax | $ 5,197 | $ 4,350 | |
Finance income and expense | 645 | 654 | |
Share of after tax losses of associates and joint ventures | 19 | 1 | |
Depreciation, amortisation and impairment | 2,534 | 2,778 | |
Movement in working capital and short-term provisions | (584) | (747) | |
Gains on disposal of intangible assets | (21) | (249) | |
Fair value movements on contingent consideration arising from business combinations | 251 | 202 | |
Non-cash and other movements | (550) | (594) | |
Cash generated from operations | 7,491 | 6,395 | |
Interest paid | (583) | (483) | |
Tax paid | (1,337) | (1,061) | |
Net cash inflow from operating activities | 5,571 | 4,851 | |
Cash flows from investing activities | |||
Acquisition of subsidiaries, net of cash acquired | (2,771) | (189) | |
Payments upon vesting of employee share awards attributable to business combinations | (23) | ||
Payment of contingent consideration from business combinations | (474) | (398) | |
Purchase of property, plant and equipment | (799) | (517) | |
Disposal of property, plant and equipment | 53 | 126 | |
Purchase of intangible assets | (1,474) | (1,436) | |
Disposal of intangible assets | 75 | 288 | |
Movement in profit-participation liability | 175 | ||
Purchase of non-current asset investments | (67) | (26) | |
Disposal of non-current asset investments | 51 | 10 | |
Movement in short-term investments, fixed deposits and other investing instruments | 42 | 90 | |
Payments to associates and joint ventures | (140) | ||
Disposal of investments in associates and joint ventures | 13 | ||
Interest received | 206 | 134 | |
Net cash outflow from investing activities | (5,285) | (1,766) | |
Net cash inflow before financing activities | 286 | 3,085 | |
Cash flows from financing activities | |||
Proceeds from issue of share capital | 11 | 8 | |
Issue of loans and borrowings | 4,976 | 3,816 | |
Repayment of loans and borrowings | (2,643) | (3,408) | |
Dividends paid | (3,050) | (3,069) | |
Hedge contracts relating to dividend payments | (8) | 27 | |
Repayment of obligations under leases | (150) | (129) | |
Movement in short-term borrowings | 2,503 | 72 | |
Payment of Acerta Pharma share purchase liability | (833) | (867) | |
Net cash inflow/(outflow) from financing activities | 806 | (3,550) | |
Net increase/(decrease) in Cash and cash equivalents in the period | 1,092 | (465) | |
Cash and cash equivalents at the beginning of the period | 5,637 | 5,983 | |
Exchange rate effects | (52) | (47) | |
Cash and cash equivalents at the end of the period | 6,677 | 5,471 | |
Cash and cash equivalents | 6,916 | [1] | 5,664 |
Overdrafts | $ (239) | $ (193) | |
[1] The Condensed consolidated statement of financial position as at 30 June 2024 and 30 June 2023 have been reviewed by PricewaterhouseCoopers LLP. The Condensed consolidated statement of financial position as at 31 December 2023 has been audited by PricewaterhouseCoopers LLP. |
Basis of preparation and accoun
Basis of preparation and accounting policies | 6 Months Ended |
Jun. 30, 2024 | |
Basis of preparation and accounting policies | |
Basis of preparation and accounting policies | Notes to the Interim financial statements Note 1: Basis of preparation and accounting policies These unaudited condensed consolidated Interim financial statements for the six months ended 30 June 2024 have been prepared in accordance with International Accounting Standard 34, ‘Interim Financial Reporting’ (IAS 34), as issued by the International Accounting Standards Board (IASB), IAS 34 as adopted by the European Union, UK-adopted IAS 34 and the Disclosure Guidance and Transparency Rules sourcebook of the United Kingdom’s Financial Conduct Authority and with the requirements of the Companies Act 2006 as applicable to companies reporting under those standards. The unaudited Interim financial statements for the six months ended 30 June 2024 were approved by the Board of Directors for publication on 25 July 2024. This results announcement does not constitute statutory accounts of the Group within the meaning of sections 434(3) and 435(3) of the Companies Act 2006. The annual financial statements of the Group for the year ended 31 December 2023 were prepared in accordance with UK-adopted international accounting standards and with the requirements of the Companies Act 2006. The annual financial statements also comply fully with IFRS Accounting Standards as issued by the IASB and International Accounting Standards as adopted by the European Union. Except for the estimation of the interim income tax charge, the Interim financial statements have been prepared applying the accounting policies that were applied in the preparation of the Group’s published consolidated financial statements for the year ended 31 December 2023. The comparative figures for the financial year ended 31 December 2023 are not the Group’s statutory accounts for that financial year. Those accounts have been reported on by the Group’s auditors and have been delivered to the Registrar of Companies; their report was (i) unqualified, (ii) did not include a reference to any matters to which the auditors drew attention by way of emphasis without qualifying their report, and (iii) did not contain a statement under section 498(2) or (3) of the Companies Act 2006. Going concern The Group has considerable financial resources available. As at 30 June 2024, the Group has $11.8bn in financial resources (cash and cash equivalent balances of $6.9bn and undrawn committed bank facilities of $4.9bn, with $5.4bn of borrowings due within one year. These facilities contain no financial covenants and were undrawn at 30 June 2024. The $4.9bn facilities are available until April 2029. Additionally, there are a further $2.0bn undrawn committed bank facilities available until February 2025. The Group’s revenues are largely derived from sales of medicines covered by patents which provide a relatively high level of resilience and predictability to cash inflows, although government price interventions in response to budgetary constraints are expected to continue to adversely affect revenues in some of our significant markets. The Group, however, anticipates new revenue streams from both recently launched medicines and those in development, and the Group has a wide diversity of customers and suppliers across different geographic areas. Consequently, the Directors believe that, overall, the Group is well placed to manage its business risks successfully. Accordingly, they continue to adopt the going concern basis in preparing the Interim financial statements. Legal proceedings The information contained in Note 6 updates the disclosures concerning legal proceedings and contingent liabilities in the Group’s Annual Report and Form 20-F Information 202 3 Employee Benefit Trust Following an amendment to the Employee Benefit Trust (EBT) Deed on 10th June 2024, AstraZeneca obtained control and commenced consolidation of the EBT. Going forward, cash paid on purchases of AstraZeneca Ordinary shares or American Depository Receipts, will be presented within Financing activities in the Cash flow statement. |
Intangible assets
Intangible assets | 6 Months Ended |
Jun. 30, 2024 | |
Intangible assets | |
Intangible assets | Note 2: Intangible assets In accordance with IAS 36 ‘Impairment of Assets’, reviews for triggers of impairment or impairment reversals at an individual asset or cash generating unit level were conducted, and impairment tests carried out where triggers were identified. As a result, total impairment charge of $26m has been recorded against intangible assets during the six months ended 30 June 2024 (H1 2023: $320m net charge). In H1 2023, net impairment charges included the $244m impairment of the ALXN1840 intangible asset, following the decision to discontinue this development programme in Wilson’s disease. The acquisition of Icosavax, Inc. completed on 19 February 2024. The transaction is recorded as an asset acquisition based on the concentration test permitted under IFRS 3, ‘Business Combinations’, with consideration of $841m principally relating to $639m of intangible assets, $141m of cash and cash equivalents and $51m of marketable securities. Contingent consideration of up to $300m could be paid on achievement of regulatory and sales milestones; these potential liabilities would be recorded when the relevant recognition event for a regulatory or sales milestone is achieved. |
Net Debt
Net Debt | 6 Months Ended |
Jun. 30, 2024 | |
Net Debt. | |
Net Debt | Note 3: Net debt The table below provides an analysis of Net debt and a reconciliation of Net Cash flow to the movement in Net debt. The Group monitors Net debt as part of its capital-management policy as described in Note 28 of the Annual Report and Form 20-F Information 202 3 Table 23: Net debt At 1 Jan Cash Non-cash Exchange At 30 Jun 2024 flow Acquisitions & other movements 2024 $m $m $m $m $m $m Non-current instalments of loans (22,365) (4,973) (3) (2) 118 (27,225) Non-current instalments of leases (857) - (12) (97) 17 (949) Total long-term debt (23,222) (4,973) (15) (99) 135 (28,174) Current instalments of loans (4,614) 2,583 (9) (5) 27 (2,018) Current instalments of leases (271) 174 (6) (197) 8 (292) Commercial paper - (2,453) - - - (2,453) Collateral received from derivative counterparties (215) 13 - - - (202) Other short-term borrowings excluding overdrafts (97) (63) - - 5 (155) Overdrafts (203) (35) - - (1) (239) Total current debt (5,400) 219 (15) (202) 39 (5,359) Gross borrowings (28,622) (4,754) (30) (301) 174 (33,533) Net derivative financial instruments 150 65 - (82) - 133 Net borrowings (28,472) (4,689) (30) (383) 174 (33,400) Cash and cash equivalents 5,840 885 242 - (51) 6,916 Other investments - current 122 (42) 87 - (7) 160 Cash and investments 5,962 843 329 - (58) 7,076 Net debt (22,510) (3,846) 299 (383) 116 (26,324) Net debt increased by $3,814m in the half year to $26,324m. Details of the committed undrawn bank facilities are disclosed within the going concern section of Note 1. Non-cash movements in the period include fair value adjustments under IFRS 9 ‘Financial Instruments’. In February 2024, AstraZeneca issued the following: - $1,250 m of fixed-rate notes with a coupon of 4.8% maturing in February 2027 - $1,250 m of fixed-rate notes with a coupon of 4.85% maturing in February 2029 - $1,000 m of fixed-rate notes with a coupon of 4.9% maturing in February 2031 - $1,500 m of fixed-rate notes with a coupon of 5% maturing in February 2034 AstraZeneca repaid two bonds of carrying value $2,569m in Q2 2024 included in the cash outflow from Repayment of loans and borrowings of $2,643m. AstraZeneca also issued Commercial paper during the half year and the balance as at 30 June 2024 is $2,453m (H1 2023: $nil). The Group has agreements with some bank counterparties whereby the parties agree to post cash collateral on financial derivatives, for the benefit of the other, equivalent to the market valuation of the derivative positions above a predetermined threshold. The carrying value of such cash collateral held by the Group at 30 June 2024 was $202m (31 December 2023: $215m) and the carrying value of such cash collateral posted by the Group at 30 June 2024 was $97m (31 December 2023: $102m). The equivalent GAAP measure to Net debt is ‘liabilities arising from financing activities’, which excludes the amounts for cash and overdrafts, other investments and non-financing derivatives shown above and includes the Acerta Pharma share purchase liability of $nil (31 December 2023: $833m). During the six months ended 30 June 2024, there have been no changes to the Company’s solicited long term credit ratings. Moody’s credit ratings were long term: A2; short term: P-1. Standard and Poor’s credit ratings were long term: A; short term: A-1 |
Financial instruments
Financial instruments | 6 Months Ended |
Jun. 30, 2024 | |
Financial instruments | |
Financial instruments | Note 4: Financial Instruments As detailed in the Group’s most recent annual financial statements, the principal financial instruments consist of derivative financial instruments, other investments, trade and other receivables, cash and cash equivalents, trade and other payables, lease liabilities and interest-bearing loans and borrowings. The Group has certain equity investments that are categorised as Level 3 in the fair value hierarchy that are held at $337m (31 December 2023: $313m) and for which a fair value gain of $1m has been recognised in the six months ended 30 June 2024 (H1 2023: $1m). In the absence of specific market data, these unlisted investments are held at fair value based on the cost of investment and adjusted as necessary for impairments and revaluations on new funding rounds, which are seen to approximate the fair value. All other fair value gains and/or losses that are presented in Net gains/(losses) on equity investments measured at fair value through other comprehensive income in the Condensed consolidated statement of comprehensive income for the six months ended 30 June 2024 are Level 1 fair value measurements, valued based on quoted prices in active markets. Financial instruments measured at fair value include $1,670m of other investments, $5,463m held in money-market funds, and $133m of derivatives as at 30 June 2024. With the exception of derivatives being Level 2 fair valued, and certain equity instruments of $350m categorised as Level 3, the aforementioned balances are Level 1 fair valued. Financial instruments measured at amortised cost include $97m of cash collateral pledged to counterparties. The total fair value of interest-bearing loans and borrowings at 30 June 2024, which have a carrying value of $33,533m in the Condensed consolidated statement of financial position, was $32,231m. Table 24: Financial instruments – contingent consideration 2024 2023 Diabetes alliance Other Total Total $m $m $m $m At 1 January 1,945 192 2,137 2,222 Additions through business combinations - 198 198 60 Settlements (473) (1) (474) (398) Revaluations 220 31 251 202 Discount unwind 50 7 57 66 At 30 June 1,742 427 2,169 2,152 Contingent consideration arising from business combinations is fair valued using decision-tree analysis, with key inputs including the probability of success, consideration of potential delays and the expected levels of future revenues. The contingent consideration balance relating to BMS’s share of the global diabetes alliance of $1,742m (31 December 2023: $1,945m) would increase/decrease by $174m with an increase/decrease in sales of 10%, as compared with the current estimates. |
Business combinations
Business combinations | 6 Months Ended |
Jun. 30, 2024 | |
Business combinations | |
Business combinations | Note 5: Business combinations Gracell On 22 February 2024, AstraZeneca completed the acquisition of Gracell Biotechnologies Inc. (Gracell), a global clinical-stage biopharmaceutical company developing innovative cell therapies for the treatment of cancer and autoimmune diseases. Gracell will operate as a wholly owned subsidiary of AstraZeneca, with operations in China and the US. The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with AZD0120 (formerly GC012F), a novel, clinical-stage T-cell (CAR-T: therapeutic chimeric antigen receptor) therapy. AZD0120 is a potential new treatment for multiple myeloma, as well as other haematologic malignancies and autoimmune diseases, including Systemic Lupus Erythematosus (SLE). The transaction is recorded as a business combination using the acquisition method of accounting in accordance with IFRS 3 ‘Business Combinations’. Consequently, the assets acquired, and liabilities assumed are recorded at fair value. Due to the proximity of the acquisition to the reporting date, the purchase price allocation exercise under IFRS 3 is in process, with the following items disclosed on a provisional basis. Fair values $m Intangible assets 1,038 Cash and cash equivalents 212 Net deferred tax liability (260) Other immaterial balances (89) Total net assets acquired 901 Goodwill 136 Consideration 1,037 The total consideration fair value of $1,037m includes cash consideration of $983m and future regulatory milestone-based consideration of $54m. Intangible assets recognised relate to products in development, principally AZD0120, and were fair valued using the multi-period excess earnings method, which uses several estimates regarding the amount and timing of future cash flows. The key assumptions in the cash flows are PTRS, peak year sales and revenue erosion profiles. The net deferred tax liability of $260m principally arises from the deferred tax impact of the uplift in fair value of intangible assets. Goodwill of $136m has been recognised, which principally comprises the premium attributable to the core technological capabilities and knowledge base of the company. Goodwill is not expected to be deductible for tax purposes. Gracell’s results have been consolidated into the Group’s results from 22 February 2024. Fusion On 4 June 2024, AstraZeneca completed the acquisition of Fusion Pharmaceuticals Inc., (Fusion) a clinical-stage biopharmaceutical company developing next-generation radioconjugates. The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments. As a result of the acquisition, Fusion became a wholly owned subsidiary of AstraZeneca, with operations in Canada and the US. This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of radioconjugates, including their most advanced programme, FPI-2265, a potential new treatment for patients with metastatic castration-resistant prostate cancer (mCRPC), and brings new expertise and pioneering R&D, manufacturing and supply chain capabilities in actinium-based radioconjugates to AstraZeneca. The transaction is recorded as a business combination using the acquisition method of accounting in accordance with IFRS 3 ‘Business Combinations’. Consequently, the assets acquired, and liabilities assumed are recorded at fair value. Due to the proximity of the acquisition to the reporting date, the purchase price allocation exercise under IFRS 3 is in process, with the following items disclosed on a provisional basis. Fair values $m Intangible assets 1,326 Cash and cash equivalents 30 Current investments 87 Net deferred tax liability (246) Other immaterial balances 51 Total net assets acquired 1,248 Goodwill 947 Consideration 2,195 The total consideration fair value of $2,195m includes cash consideration of $2,051m and future regulatory milestone-based consideration of $144m. Intangible assets relating to products in development comprise the FPI-2265 ($848m), FPI-2059 ($165m) and AZD2068 ($313m) programmes. These were fair valued using the multi-period excess earnings method, which uses several estimates regarding the amount and timing of future cash flows. The key assumptions in the cash flows are PTRS, peak year sales and revenue erosion profiles. The net deferred tax liability of $246m principally arises from the deferred tax impact of the uplift in fair value of intangible assets. Goodwill recognised comprises a number of not individually quantifiable elements. These include the premium attributable to a pre-existing well positioned business in the innovation intensive biopharmaceuticals market with a highly skilled workforce, unidentified potential products that future research and development may yield, and the core capabilities and knowledge base of the company including radioisotope supply and manufacturing expertise. Goodwill is not expected to be deductible for tax purposes. Immediately prior to the acquisition, AstraZeneca held an approximately 1% shareholding in Fusion considered to have a fair value of $24m. Fusion’s results have been consolidated into the Group’s results from 4 June 2024. |
Legal proceedings and contingen
Legal proceedings and contingent liabilities | 6 Months Ended |
Jun. 30, 2024 | |
Legal proceedings and contingent liabilities | |
Legal proceedings and contingent liabilities | Note 6: Legal proceedings and contingent liabilities AstraZeneca is involved in various legal proceedings considered typical to its business, including litigation and investigations, including Government investigations, relating to product liability, commercial disputes, infringement of intellectual property (IP) rights, the validity of certain patents, anti-trust law and sales and marketing practices. The matters discussed below constitute the more significant developments since publication of the disclosures concerning legal proceedings in the Company's Annual Report and Form 20-F Information 2023 (the Disclosures). Information about the nature and facts of the cases is disclosed in accordance with IAS 37. As discussed in the Disclosures, the majority of claims involve highly complex issues. Often these issues are subject to substantial uncertainties and, therefore, the probability of a loss, if any, being sustained and/or an estimate of the amount of any loss is difficult to ascertain. In cases that have been settled or adjudicated, or where quantifiable fines and penalties have been assessed and which are not subject to appeal, or where a loss is probable and we are able to make a reasonable estimate of the loss, AstraZeneca records the loss absorbed or makes a provision for its best estimate of the expected loss. The position could change over time and the estimates that the Company made, and upon which the Company have relied in calculating these provisions are inherently imprecise. There can, therefore, be no assurance that any losses that result from the outcome of any legal proceedings will not exceed the amount of the provisions that have been booked in the accounts. The major factors causing this uncertainty are described more fully in the Disclosures and herein. AstraZeneca has full confidence in, and will vigorously defend and enforce, its IP. Matters disclosed in respect of the second quarter of 2024 and to 25 July 2024 Patent litigation Legal proceedings brought against AstraZeneca considered to be contingent liabilities Enhertu US patent proceedings In October 2020, Seagen Inc. (Seagen) filed a complaint against Daiichi Sankyo Company, Limited (Daiichi Sankyo) in the US District Court for the Eastern District of Texas (District Court) alleging that Enhertu Enhertu Enhertu In December 2020 and January 2021, AstraZeneca and Daiichi Sankyo, Inc. filed post-grant review (PGR) petitions with the US Patent and Trademark Office (USPTO) alleging, among other things, that the Seagen patent is invalid for lack of written description and enablement. The USPTO initially declined to institute the PGRs, but, in April 2022, the USPTO granted the rehearing requests and instituted both PGR petitions. Seagen subsequently disclaimed all patent claims at issue in one of the PGR proceedings. In July 2022, the USPTO reversed its institution decision and declined to institute the other PGR petition. AstraZeneca and Daiichi Sankyo, Inc. requested reconsideration of the decision not to institute review of the patent. In February 2023, the USPTO reinstituted the PGR proceeding. In February 2024, the USPTO issued a decision that the claims were unpatentable. Seagen has appealed this decision. Tagrisso US patent proceedings In September 2021, Puma Biotechnology, Inc. (Puma) and Wyeth LLC (Wyeth) filed a patent infringement lawsuit in the US District Court for the District of Delaware (District Court) against AstraZeneca relating to Tagrisso Legal proceedings brought by AstraZeneca considered to be contingent assets Calquence US patent proceedings In February 2022, in response to Paragraph IV notices from multiple ANDA filers, AstraZeneca filed patent infringement lawsuits in the US District Court for the District of Delaware (District Court). In its complaint, AstraZeneca alleged that a generic version of Calquence Calquence In April 2024, AstraZeneca received a Paragraph IV notice from an ANDA filer relating to patents listed in the FDA Orange Book with reference to Calquence Calquence Lokelma US patent proceedings In August 2022, in response to Paragraph IV notices, AstraZeneca initiated ANDA litigation against multiple generic filers in the US District Court for the District of Delaware (District Court). AstraZeneca alleged that a generic version of Lokelma AstraZeneca entered into separate settlement agreements with two generic manufacturers which resulted in dismissal of the corresponding litigations. Additional proceedings with the remaining generic manufacturers are ongoing in the District Court. Trial is scheduled for March 2025. Lynparza US patent proceedings In December 2022, AstraZeneca received a Paragraph IV notice from Natco Pharma Limited (Natco) relating to Lynparza Lynparza In December 2023, AstraZeneca received a Paragraph IV notice from Sandoz Inc. (Sandoz) relating to Lynparza Lynparza In May 2024, AstraZeneca filed additional ANDA actions against Natco and Sandoz asserting recently issued patents covering Lynparza. In May 2024, AstraZeneca received a Paragraph IV notice from Cipla USA, Inc. and Cipla Limited (collectively, Cipla) relating to Lynparza Lynparza, Soliris US patent proceedings In January 2024, Alexion initiated patent infringement litigation against Samsung Bioepis Co. Ltd. (Samsung) in the US District Court for the District of Delaware alleging that Samsung’s biosimilar eculizumab Soliris inter partes A eculizumab European patent proceedings In March 2024, Alexion filed motions for provisional measures against Amgen Pharmaceuticals Inc (Amgen) and Samsung Bioepis Co. Ltd. (Samsung) and their respective affiliates at the Hamburg Local Division of the Unified Patent Court on the basis that Amgen’s and Samsung’s biosimilar eculizumab products infringe an Alexion patent. In June 2024 the UPC denied the requested provisional measures. Alexion has appealed this decision. In parallel, Samsung has filed opposition to the patent at the European Patent Office. UK patent proceedings In May 2024, Alexion initiated patent infringement proceedings against Amgen Ltd and Samsung Bioepis UK Ltd (Samsung UK) in the UK High Court of Justice alleging that their respective biosimilar eculizumab products infringe an Alexion patent; on the same day, Samsung UK initiated a revocation action for the same patent. Trial has been scheduled for March 2025. Tagrisso Russia patent proceedings In Russia, in August 2023, AstraZeneca filed lawsuits in the Arbitration Court of the Moscow Region (Court) against the Ministry of Health of the Russian Federation and Axelpharm LLC (Axelpharm) related to Axelpharm’s improper use of AstraZeneca’s information to obtain authorisation to market a generic version of Tagrisso In Russia, in November 2023, Axelpharm filed a compulsory licensing action against AstraZeneca in the Court related to a patent that covers Tagrisso In July 2024, AstraZeneca filed a patent infringement lawsuit and an unfair competition claim with the Federal Anti-Monopoly Service of Russia against AxelPharm and others related to the securing of state contracts in Russia for its generic version of osimertinib Commercial litigation Legal proceedings brought against AstraZeneca considered to be contingent liabilities Anti-Terrorism Act Civil Lawsuit US proceedings In the US, in October 2017, AstraZeneca and certain other pharmaceutical and/or medical device companies were named as defendants in a complaint filed in the US District Court for the District of Columbia (District Court) by US nationals (or their estates, survivors, or heirs) who were killed or wounded in Iraq between 2005 and 2013. The plaintiffs allege that the defendants violated the US Anti-Terrorism Act and various state laws by selling pharmaceuticals and medical supplies to the Iraqi Ministry of Health. In July 2020, the District Court granted AstraZeneca’s and the other defendants’ motion to dismiss the lawsuit, which the DC Circuit Court of Appeals (the Appellate Court) reversed in January 2022. In June 2024, the United States Supreme Court issued an order vacating the 2022 decision and granted AstraZeneca’s and the other defendants’ request for a remand to the Appellate Court for reconsideration under new case law. Employment Litigation US proceedings In December 2022, AstraZeneca was served with a lawsuit filed by seven former employees in the US District Court for the District of Delaware (District Court) asserting claims of discrimination on grounds of age and religion, related to AstraZeneca’s vaccination requirement. In March 2023, AstraZeneca filed a partial motion to dismiss certain religious discrimination claims and a motion to strike the class and collective claims. In September 2023, Plaintiffs moved for conditional certification of the collective action. In June 2024, the District Court granted AstraZeneca’s partial motion to dismiss, granted AstraZeneca’s motion to strike, and denied without prejudice Plaintiff’s motion for conditional certification. Pay Equity Litigation US proceedings AstraZeneca is defending a putative class and collective action in the US District Court for the Northern District of Illinois (District Court) brought by three named plaintiffs, who are former AstraZeneca employees. The case involves claims under the federal and Illinois Equal Pay Acts, with the plaintiffs alleging they were paid less than male employees who performed substantially similar and/or equal work. In May 2024, the District Court conditionally certified a collective under the federal Equal Pay Act and authorised the sending of notice to potential collective action members. The notice was distributed in June 2024. University of Sheffield Contract Dispute UK proceedings In June 2024, AstraZeneca was served with a lawsuit filed by the University of Sheffield (Sheffield). In its complaint, Sheffield alleges that AstraZeneca made misrepresentations to induce Sheffield to amend a patent license relating to Lynparza. AstraZeneca is considering its response Viela Bio, Inc. Shareholder Litigation US proceedings In February 2023, AstraZeneca was served with a lawsuit filed in Delaware state court against AstraZeneca and certain officers (collectively, Defendants), on behalf of a putative class of Viela Bio, Inc. (Viela) shareholders. The complaint alleged that the Defendants breached their fiduciary duty to Viela shareholders in the course of Viela’s 2021 merger with Horizon Therapeutics, plc. In July 2024, the Court granted with prejudice AstraZeneca’s motion to dismiss. Financial State me nts Legal proceedings brought by AstraZeneca considered to be contingent assets PARP Inhibitor Royalty Dispute UK proceedings In October 2012, Tesaro, Inc. (now wholly owned by GlaxoSmithKline plc, (GSK)) entered into two worldwide, royalty-bearing patent license agreements with AstraZeneca related to GSK’s product niraparib niraparib Government investigations/proceedings Legal proceedings brought against AstraZeneca considered to be contingent liabilities Boston US Attorney Investigation US Proceedings In June 2024, AstraZeneca was served with a subpoena issued by the US Attorney’s Office in Boston, seeking documents and information relating to payments by AstraZeneca to healthcare providers. AstraZeneca is cooperating with this enquiry. Turkish Ministry of Health Matter Turkey proceedings In Turkey, in July 2020, the Turkish Ministry of Health (Ministry of Health) initiated an investigation regarding payments to healthcare providers by Alexion and former employees and consultants. The investigation arose from Alexion’s disclosure of a $21.5m civil settlement with the US Securities & Exchange Commission (SEC) in July 2020 fully resolving the SEC’s investigation into possible violations of the US Foreign Corrupt Practices Act. In September 2021, the Ministry of Health completed its draft investigation report, and referred the matter to the Ankara Public Prosecutor’s Office with a recommendation for further proceedings against certain former employees. In June 2024, the Ankara Public Prosecutor’s Office closed its investigation without further action. Legal proceedings brought by AstraZeneca considered to be contingent assets Inflation Reduction Act Litigation US proceedings In August 2023, AstraZeneca filed a lawsuit in the US District Court for the District of Delaware (District Court) against the US Department of Health and Human Services (HHS) challenging aspects of the drug price negotiation provisions of the Inflation Reduction Act and the implementing guidance and regulations. In March 2024, the District Court granted HHS’ motions and dismissed AstraZeneca’s lawsuit. AstraZeneca has appealed the District Court’s decision. 340B State Litigation US proceedings AstraZeneca has filed lawsuits against Arkansas, Kansas, Louisiana, Maryland, Minnesota, Mississippi, and West Virginia challenging the constitutionality of each state’s 340B statute. In the Arkansas matter, trial is scheduled for April 2025. In the Louisiana matter, AstraZeneca and the state have filed motions for summary judgment and a hearing was held in June 2024. The remaining matters are in their preliminary stages. Other Additional government inquiries As is true for most, if not all, major prescription pharmaceutical companies, AstraZeneca is currently involved in multiple inquiries into drug marketing and pricing practices. In addition to the investigations described above, various law enforcement offices have, from time to time, requested information from the Group. There have been no material developments in those matters. Matters disclosed in respect of the first quarter of 2024 and to 25 April 2024 Patent litigation Legal proceedings brought against AstraZeneca considered to be contingent liabilities Forxiga UK patent proceedings In the UK, one of AstraZeneca’s patents relating to Forxiga Tagrisso US patent proceedings In September 2021, Puma Biotechnology, Inc. (Puma) and Wyeth LLC (Wyeth) filed a patent infringement lawsuit in the US District Court for the District of Delaware (District Court) against AstraZeneca relating to Tagrisso Legal proceedings brought by AstraZeneca considered to be contingent assets Calquence US patent proceedings In February 2022, in response to Paragraph IV notices from multiple ANDA filers, AstraZeneca filed patent infringement lawsuits in the US District Court for the District of Delaware (District Court). In its complaint, AstraZeneca alleged that a generic version of Calquence In March and April 2024, AstraZeneca entered into settlement agreements with generic manufacturers, Sandoz Inc., and Natco Pharma Limited with Natco Pharma Inc., resulting in dismissal of the corresponding Calquence Calquence In April 2024, AstraZeneca received a Paragraph IV notice from an ANDA filer relating to patents listed in the FDA Orange Book with reference to Calquence Lokelma US patent proceedings In August 2022, in response to Paragraph IV notices, AstraZeneca initiated ANDA litigation against multiple generic filers in the US District Court for the District of Delaware (District Court). Trial is scheduled for March 2025. AstraZeneca entered into a settlement agreement with a generic manufacturer, Alkem Laboratories, which resulted in dismissal of the corresponding litigation. Additional proceedings with the remaining generic manufacturers are ongoing in the District Court. Soliris US patent proceedings In January 2024, Alexion initiated patent infringement litigation against Samsung Bioepis Co. Ltd. (Samsung) in the US District Court for the District of Delaware alleging that Samsung’s biosimilar eculizumab product, for which Samsung is currently seeking FDA approval, will infringe six Soliris European patent proceedings In March 2024, Alexion filed motions for preliminary injunctions against Amgen and Samsung at the Hamburg Local Division of the Unified Patent Court on the basis that Amgen’s and Samsung’s biosimilar eculizumab products infringe Alexion’s eculizumab molecule patent that is expected to grant in Q2 2024. No hearing date for the preliminary injunction motions has been set. Tagrisso Russia patent proceedings In Russia, in August 2023, AstraZeneca filed lawsuits in the Arbitration Court of the Moscow Region (Court) against the Ministry of Health of the Russian Federation and Axelpharm LLC (Axelpharm) related to Axelpharm’s improper use of AstraZeneca’s information to obtain authorisation to market a generic version of Tagrisso In Russia, in November 2023, Axelpharm filed a compulsory licensing action against AstraZeneca in the Court related to a patent that covers Tagrisso Product liability litigation Legal proceedings brought against AstraZeneca for which a provision has been taken Nexium and Losec / Prilosec US proceedings AstraZeneca has been defending lawsuits brought in federal and state courts involving claims that plaintiffs have been diagnosed with various injuries following treatment with proton pump inhibitors (PPIs), including Nexium and Prilosec. Most of the lawsuits alleged kidney injury. In August 2017, the pending federal court cases were consolidated into a multidistrict litigation (MDL) proceeding in the US District Court for the District of New Jersey for pre-trial purposes. Cases alleging kidney injury were also filed in Delaware and New Jersey state courts. In addition, AstraZeneca has been defending lawsuits involving allegations of gastric cancer following treatment with PPIs, including one such claim in the US District Court for the Middle District of Louisiana (Louisiana District Court). In October 2023, AstraZeneca resolved all pending claims in the MDL, as well as all pending claims in Delaware and New Jersey state courts, for $425m, for which a provision has been taken. The only remaining case is the one pending in the Louisiana District Court, which is scheduled for trial in January 2025. Canada proceedings In Canada, in July and August 2017, AstraZeneca was served with three putative class action lawsuits. Two of the lawsuits have been dismissed, one in 2019 and one in 2021. The third lawsuit seeks authorisation to represent individual residents in Canada who allegedly suffered kidney injuries from the use of proton pump inhibitors, including Nexium Legal proceedings brought against AstraZeneca considered to be contingent liabilities Onglyza and Kombiglyze US proceedings In the US, AstraZeneca has been defending various lawsuits in both California state court and in a consolidated federal proceeding alleging heart failure, cardiac injuries, and/or death from treatment with Onglyza Kombiglyze Vaxzevria UK proceedings AstraZeneca is defending lawsuits in the UK involving multiple claimants alleging injuries following vaccination with AstraZeneca’s COVID-19 vaccine. Most of the lawsuits involve claims of thrombosis with thrombocytopenia syndrome. No trial dates have been scheduled. Commercial litigation Legal proceedings brought against AstraZeneca considered to be contingent liabilities 340B Antitrust Litigation US proceedings In September 2021, AstraZeneca was served with a class-action antitrust complaint filed in the US District Court for the Western District of New York (District Court) by Mosaic Health alleging a conspiracy to restrict access to 340B discounts in the diabetes market through contract pharmacies. In September 2022, the District Court granted AstraZeneca’s motion to dismiss the Complaint. In February 2024, the District Court denied Plaintiffs’ request to file an amended complaint and entered an order closing the matter. In March 2024, Plaintiffs filed an appeal. Definiens Germany proceedings In Germany, in July 2020, AstraZeneca received a notice of arbitration filed with the German Institution of Arbitration from the sellers of Definiens AG (the Sellers) regarding the 2014 Share Purchase Agreement (SPA) between AstraZeneca and the Sellers. The Sellers claim that they are owed approximately $140m in earn-outs under the SPA. In December 2023, after an arbitration hearing, the arbitration panel made a final award of $46.43m in favour of the Sellers. In March 2024, AstraZeneca filed an application with the Bavarian Supreme Court to set aside the arbitration award. Financial State me nts Legal proceedings brought by AstraZeneca considered to be contingent assets PARP Inhibitor Royalty Dispute UK proceedings In October 2012, Tesaro, Inc. (now wholly owned by GlaxoSmithKline plc, (GSK)) entered into two worldwide, royalty-bearing patent license agreements with AstraZeneca related to GSK’s product niraparib niraparib Government investigations/proceedings Legal proceedings brought against AstraZeneca considered to be contingent liabilities 340B Qui Tam US proceedings In July 2023, AstraZeneca was served with an unsealed civil lawsuit brought by a qui tam relator on behalf of the United States, several states, and the District of Columbia in the US District Court for the Central District of California (District Court). The complaint alleges that AstraZeneca violated the US False Claims Act and state law analogues. In March 2024, the District Court granted AstraZeneca’s motion to dismiss the First Amended Complaint without leave to amend. In April 2024, the relator filed an appeal. Legal proceedings brought by AstraZeneca considered to be contingent assets Inflation Reduction Act Litigation US proceedings In August 2023, AstraZeneca filed a lawsuit in the US District Court for the District of Delaware (District Court) against the US Department of Health and Human Services (HHS) challenging aspects of the drug price negotiation provisions of the Inflation Reduction Act and the implementing guidance and regulations. In March 2024, the District Court granted HHS’ motions and dismissed AstraZeneca’s lawsuit. Arkansas 340B Litigation US proceedings In March 2024, AstraZeneca filed a lawsuit against the State of Arkansas alleging that the Arkansas’s 340B statute is preempted by federal law and unconstitutional. Other Additional government inquiries As is true for most, if not all, major prescription pharmaceutical companies, AstraZeneca is currently involved in multiple inquiries into drug marketing and pricing practices. In addition to the investigations described above, various law enforcement offices have, from time to time, requested information from the Group. There have been no material developments in those matters. |
Subsequent Events
Subsequent Events | 6 Months Ended |
Jun. 30, 2024 | |
Subsequent Events | |
Subsequent Events | Note 7 : Subsequent events On 15 July 2024, AstraZeneca completed the acquisition of Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases. AstraZeneca acquired all outstanding equity of Amolyt for a total consideration of up to $1.05 billion, on a cash and debt free basis. This includes an initial payment of $800m on deal closing, subject to customary closing adjustments, and a further up to $250m in contingent milestones-based consideration. Due to the timing of the transaction post period end, the accounting and other disclosures will be finalised in the second half of 2024. |
H1 2024 - Product Sales year-on
H1 2024 - Product Sales year-on-year analysis | 6 Months Ended |
Jun. 30, 2024 | |
H1 2024 - Product Sales year-on-year analysis | |
H1 2024 - Product Sales year-on-year analysis | Table 25: H1 2024 - Product Sales year-on-year analysis 15 The CER information in respect of H1 2024 included in the Interim financial statements has not been reviewed by PricewaterhouseCoopers LLP. World US Emerging Markets Europe Established RoW $m Act % chg CER % chg $m % chg $m Act % chg CER % chg $m Act % chg CER % chg $m Act % chg CER % chg Oncology 9,737 17 21 4,387 20 2,300 18 28 1,967 25 23 1,083 (2) 8 Tagrisso 3,203 10 13 1,282 16 919 8 16 628 16 15 374 (11) (2) Imfinzi 2,259 20 25 1,202 17 245 35 58 459 38 36 353 7 19 Calquence 1,508 27 28 1,048 21 75 82 n/m 320 42 41 65 30 34 Lynparza 1,450 6 9 607 5 320 15 26 398 9 8 125 (14) (6) Enhertu 249 n/m n/m - - 161 n/m n/m 57 n/m n/m 31 n/m n/m Zoladex 549 19 27 8 20 415 22 31 77 16 14 49 2 12 Imjudo 136 35 38 88 30 7 n/m n/m 16 n/m n/m 25 (5) 6 Truqap 142 n/m n/m 141 n/m - - - - - - 1 n/m n/m Orpathys 25 14 19 - - 25 14 19 - - - - - - Others 216 (21) (15) 11 6 133 (21) (15) 12 (36) (36) 60 (21) (12) BioPharmaceuticals: CVRM 6,164 18 22 1,483 16 2,749 17 24 1,559 33 32 373 (8) 2 Farxiga 3,785 35 38 867 37 1,474 37 44 1,233 45 44 211 (15) (5) Brilinta 665 - 2 354 (1) 166 4 14 136 - (1) 9 (26) (19) Crestor 589 1 6 22 (18) 475 4 9 22 (30) (29) 70 3 13 Seloken / Toprol-XL 315 (8) (1) - n/m 307 (8) (1) 6 4 7 2 (39) (37) Lokelma 249 26 30 115 10 42 75 83 41 62 61 51 16 31 roxadustat 163 22 27 - - 163 22 27 - - - - n/m n/m Andexxa 105 18 21 42 14 2 n/m n/m 40 38 36 21 (9) 4 Wainua 21 n/m n/m 21 n/m - - - - - - - - - Others 272 (30) (28) 62 (50) 120 (27) (22) 81 (10) (10) 9 (7) (5) BioPharmaceuticals: R&I 3,601 17 20 1,567 21 1,032 16 23 680 17 16 322 7 12 Symbicort 1,491 16 19 598 38 450 11 21 286 - (1) 157 (4) (2) Fasenra 781 5 6 478 2 41 45 53 192 9 8 70 (2) 6 Pulmicort 379 10 14 8 (53) 317 16 22 37 1 (1) 17 (13) (9) Breztri 454 48 51 225 37 131 61 69 65 80 79 33 33 44 Tezspire 100 n/m n/m - - 5 n/m n/m 61 n/m n/m 34 n/m n/m Saphnelo 203 77 77 184 71 2 n/m n/m 10 n/m n/m 7 86 91 Airsupra 21 n/m n/m 21 n/m - - - - - - - - - Others 172 (27) (26) 53 (47) 86 (18) (14) 29 3 2 4 (12) (10) BioPharmaceuticals: V&I 324 (27) (24) 55 n/m 131 (12) (7) 81 (28) (30) 57 (68) (65) Synagis 253 (11) (6) (1) n/m 131 4 10 67 (27) (29) 56 (15) (6) Beyfortus 54 n/m n/m 53 n/m - - - - (81) (61) 1 n/m n/m FluMist 8 n/m n/m 3 n/m - - - 5 n/m 97 - n/m n/m COVID-19 mAbs 3 (98) (98) - - - n/m n/m 3 (58) (59) - n/m n/m Others 6 (79) (80) - - - n/m n/m 6 (41) (43) - n/m n/m Rare Disease 4,243 11 15 2,517 10 454 40 70 794 3 2 478 9 20 Ultomiris 1,804 32 35 1,032 27 66 n/m n/m 411 32 31 295 42 58 Soliris 1,439 (13) (8) 808 (9) 255 19 54 260 (29) (30) 116 (33) (30) Strensiq 653 16 18 529 17 31 30 47 48 14 12 45 4 15 Koselugo 247 55 64 101 13 83 n/m n/m 45 95 92 18 n/m n/m Kanuma 100 17 20 47 18 19 7 20 30 24 25 4 11 20 Other medicines 560 (9) (2) 52 (24) 385 (1) 8 53 10 10 70 (35) (29) Nexium 459 (7) 1 47 (22) 318 4 15 26 3 2 68 (34) (28) Others 101 (17) (14) 5 (40) 67 (22) (18) 27 18 19 2 (53) (49) Total Product Sales 24,629 15 18 10,061 17 7,051 16 26 5,134 21 19 2,383 (6) 3 15 The table provides an analysis of year-on-year Product Sales, with Actual and CER growth rates reflecting year-on-year growth. Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. |
Q2 2024 Product Sales year-on-y
Q2 2024 Product Sales year-on-year analysis | 6 Months Ended |
Jun. 30, 2024 | |
Q2 2024 Product Sales year-on-year analysis | |
Q2 2024 Product Sales year-on-year analysis | Table 26: Q2 2024 - Product Sales year-on-year analysis (Unreviewed) 16 The Q2 2024 information in respect of the three months ended 30 June 2024 included in the Interim financial statements has not been reviewed by PricewaterhouseCoopers LLP. World US Emerging Markets Europe Established RoW $m Act % chg CER % chg $m % chg $m Act % chg CER % chg $m Act % chg CER % chg $m Act % chg CER % chg Oncology 4,976 14 18 2,302 17 1,098 11 22 1,015 24 24 561 (9) 2 Tagrisso 1,608 8 12 658 13 432 6 15 327 15 15 191 (12) (1) Imfinzi 1,147 13 18 620 15 117 16 39 227 33 33 183 (9) 3 Calquence 790 21 22 554 14 36 51 72 167 42 43 33 20 23 Lynparza 744 4 7 319 3 153 8 18 206 10 11 66 (15) (6) Enhertu 127 89 99 - - 77 60 72 31 n/m n/m 19 n/m n/m Zoladex 273 17 25 5 29 201 17 28 42 23 21 25 6 17 Imjudo 74 17 19 49 37 4 n/m n/m 8 64 55 13 (38) (30) Truqap 92 n/m n/m 91 n/m - - - - - - 1 n/m n/m Orpathys 12 (7) (3) - - 12 (7) (3) - - - - - - Others 109 (17) (11) 6 24 66 (16) (10) 7 (11) (10) 30 (26) (16) BioPharmaceuticals: CVRM 3,153 18 22 735 11 1,384 17 24 843 38 38 191 (14) (3) Farxiga 1,940 29 32 394 16 763 32 39 680 49 49 103 (23) (14) Brilinta 342 3 5 191 7 78 (1) 6 69 1 1 4 (38) (23) Crestor 292 4 11 12 (2) 234 8 14 10 (34) (32) 36 3 15 Seloken / Toprol-XL 150 (8) - - n/m 146 (8) - 3 46 53 1 (40) (38) Lokelma 136 36 41 64 29 21 68 78 23 63 64 28 16 33 roxadustat 88 20 26 - - 88 20 26 - - - - - - Andexxa 59 29 35 22 34 1 n/m n/m 22 51 51 14 (6) 8 Wainua 16 n/m n/m 16 n/m - - - - - - - - - Others 130 (26) (24) 36 (45) 53 (19) (14) 36 (9) (8) 5 (14) (12) BioPharmaceuticals: R&I 1,797 21 24 830 23 444 23 34 350 21 21 173 8 14 Symbicort 722 20 25 299 49 197 12 25 143 4 5 83 (4) (1) Fasenra 423 4 5 268 - 19 33 46 99 11 11 37 3 11 Pulmicort 155 25 30 3 (53) 126 40 47 17 6 2 9 (18) (13) Breztri 235 44 47 120 43 61 42 49 35 68 69 19 26 37 Tezspire 57 n/m n/m - - 3 n/m n/m 35 n/m n/m 19 n/m n/m Saphnelo 112 65 65 101 59 1 28 n/m 6 n/m n/m 4 90 86 Airsupra 14 n/m n/m 14 n/m - - - - - - - - - Others 79 (24) (22) 25 (52) 37 7 12 15 2 3 2 (6) (4) BioPharmaceuticals: V&I 112 28 42 28 n/m 41 (10) 4 7 (55) (53) 36 36 55 Synagis 81 (6) 8 (1) n/m 41 (16) (2) 6 (42) (42) 35 27 46 Beyfortus 28 n/m n/m 27 n/m - - - - n/m (91) 1 n/m n/m FluMist 2 n/m n/m 2 n/m - - - - (26) (21) - - - COVID-19 mAbs 1 n/m n/m - - - n/m n/m 1 (65) (64) - (99) (99) Others - n/m n/m - - - - - - n/m n/m - - - Rare Disease 2,147 10 14 1,311 10 203 35 67 392 3 3 241 7 18 Ultomiris 946 33 36 550 27 35 n/m n/m 209 38 38 152 38 56 Soliris 700 (14) (8) 398 (11) 129 30 74 118 (36) (36) 55 (36) (33) Strensiq 340 13 14 283 14 10 7 15 24 13 13 23 4 17 Koselugo 114 43 45 55 13 24 73 80 26 n/m n/m 9 63 85 Kanuma 47 3 8 25 21 5 (54) (49) 15 28 33 2 11 41 Other medicines 267 (11) (5) 28 (13) 179 (3) 5 24 (7) (7) 36 (38) (32) Nexium 219 (12) (5) 25 (17) 146 (2) 7 13 (5) (5) 35 (37) (32) Others 48 (9) (6) 3 39 33 (8) (4) 11 (9) (9) 1 (54) (49) Total Product Sales 12,452 14 18 5,234 16 3,349 15 25 2,631 23 23 1,238 (5) 5 16 The table provides an analysis of year-on-year Product Sales, with Actual and CER growth rates reflecting year-on-year growth. Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. |
Alliance Revenue
Alliance Revenue | 6 Months Ended |
Jun. 30, 2024 | |
Alliance revenue [Abstract] | |
Alliance revenue | Table 27: Alliance Revenue H1 2024 H1 2023 $m $m Enhertu 683 475 Tezspire 180 105 Beyfortus 26 - Other Alliance Revenue 50 47 Total 939 627 |
Collaboration Revenue
Collaboration Revenue | 6 Months Ended |
Jun. 30, 2024 | |
Collaboration Revenue. | |
Collaboration Revenue | Table 28: Collaboration Revenue H1 2024 H1 2023 $m $m Farxiga 49 25 COVID-19 mAbs: licence fees - 180 Other Collaboration Revenue - 15 Total 49 220 |
Other operating income and expe
Other operating income and expense | 6 Months Ended |
Jun. 30, 2024 | |
Other operating income and expense | |
Other operating income and expense | Table 29: Other operating income and expense H1 2024 H1 2023 $m $m brazikumab licence termination funding - 75 Divestment of US rights to Pulmicort Flexhaler - 241 Update to the contractual relationships for Beyfortus (nirsevimab) - 712 Other 127 135 Total 127 1,163 |
Basis of preparation and acco_2
Basis of preparation and accounting policies (Policies) | 6 Months Ended |
Jun. 30, 2024 | |
Basis of preparation and accounting policies | |
Basis of preparation and accounting policies | These unaudited condensed consolidated Interim financial statements for the six months ended 30 June 2024 have been prepared in accordance with International Accounting Standard 34, ‘Interim Financial Reporting’ (IAS 34), as issued by the International Accounting Standards Board (IASB), IAS 34 as adopted by the European Union, UK-adopted IAS 34 and the Disclosure Guidance and Transparency Rules sourcebook of the United Kingdom’s Financial Conduct Authority and with the requirements of the Companies Act 2006 as applicable to companies reporting under those standards. The unaudited Interim financial statements for the six months ended 30 June 2024 were approved by the Board of Directors for publication on 25 July 2024. This results announcement does not constitute statutory accounts of the Group within the meaning of sections 434(3) and 435(3) of the Companies Act 2006. The annual financial statements of the Group for the year ended 31 December 2023 were prepared in accordance with UK-adopted international accounting standards and with the requirements of the Companies Act 2006. The annual financial statements also comply fully with IFRS Accounting Standards as issued by the IASB and International Accounting Standards as adopted by the European Union. Except for the estimation of the interim income tax charge, the Interim financial statements have been prepared applying the accounting policies that were applied in the preparation of the Group’s published consolidated financial statements for the year ended 31 December 2023. The comparative figures for the financial year ended 31 December 2023 are not the Group’s statutory accounts for that financial year. Those accounts have been reported on by the Group’s auditors and have been delivered to the Registrar of Companies; their report was (i) unqualified, (ii) did not include a reference to any matters to which the auditors drew attention by way of emphasis without qualifying their report, and (iii) did not contain a statement under section 498(2) or (3) of the Companies Act 2006. |
Going concern | Going concern The Group has considerable financial resources available. As at 30 June 2024, the Group has $11.8bn in financial resources (cash and cash equivalent balances of $6.9bn and undrawn committed bank facilities of $4.9bn, with $5.4bn of borrowings due within one year. These facilities contain no financial covenants and were undrawn at 30 June 2024. The $4.9bn facilities are available until April 2029. Additionally, there are a further $2.0bn undrawn committed bank facilities available until February 2025. The Group’s revenues are largely derived from sales of medicines covered by patents which provide a relatively high level of resilience and predictability to cash inflows, although government price interventions in response to budgetary constraints are expected to continue to adversely affect revenues in some of our significant markets. The Group, however, anticipates new revenue streams from both recently launched medicines and those in development, and the Group has a wide diversity of customers and suppliers across different geographic areas. Consequently, the Directors believe that, overall, the Group is well placed to manage its business risks successfully. Accordingly, they continue to adopt the going concern basis in preparing the Interim financial statements. |
Legal proceedings | Legal proceedings The information contained in Note 6 updates the disclosures concerning legal proceedings and contingent liabilities in the Group’s Annual Report and Form 20-F Information 202 3 |
Employee Benefit Trust | Employee Benefit Trust Following an amendment to the Employee Benefit Trust (EBT) Deed on 10th June 2024, AstraZeneca obtained control and commenced consolidation of the EBT. Going forward, cash paid on purchases of AstraZeneca Ordinary shares or American Depository Receipts, will be presented within Financing activities in the Cash flow statement. |
Net Debt (Tables)
Net Debt (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Net Debt. | |
Schedule of Net Debt | At 1 Jan Cash Non-cash Exchange At 30 Jun 2024 flow Acquisitions & other movements 2024 $m $m $m $m $m $m Non-current instalments of loans (22,365) (4,973) (3) (2) 118 (27,225) Non-current instalments of leases (857) - (12) (97) 17 (949) Total long-term debt (23,222) (4,973) (15) (99) 135 (28,174) Current instalments of loans (4,614) 2,583 (9) (5) 27 (2,018) Current instalments of leases (271) 174 (6) (197) 8 (292) Commercial paper - (2,453) - - - (2,453) Collateral received from derivative counterparties (215) 13 - - - (202) Other short-term borrowings excluding overdrafts (97) (63) - - 5 (155) Overdrafts (203) (35) - - (1) (239) Total current debt (5,400) 219 (15) (202) 39 (5,359) Gross borrowings (28,622) (4,754) (30) (301) 174 (33,533) Net derivative financial instruments 150 65 - (82) - 133 Net borrowings (28,472) (4,689) (30) (383) 174 (33,400) Cash and cash equivalents 5,840 885 242 - (51) 6,916 Other investments - current 122 (42) 87 - (7) 160 Cash and investments 5,962 843 329 - (58) 7,076 Net debt (22,510) (3,846) 299 (383) 116 (26,324) |
Financial instruments (Tables)
Financial instruments (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Financial instruments | |
Schedule of Contingent consideration | 2024 2023 Diabetes alliance Other Total Total $m $m $m $m At 1 January 1,945 192 2,137 2,222 Additions through business combinations - 198 198 60 Settlements (473) (1) (474) (398) Revaluations 220 31 251 202 Discount unwind 50 7 57 66 At 30 June 1,742 427 2,169 2,152 |
Business combinations (Tables)
Business combinations (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Gracell Biotechnologies Inc. | |
Disclosure of detailed information about business combination [line items] | |
Schedule of business combination | Fair values $m Intangible assets 1,038 Cash and cash equivalents 212 Net deferred tax liability (260) Other immaterial balances (89) Total net assets acquired 901 Goodwill 136 Consideration 1,037 |
Fusion Pharmaceuticals Inc. | |
Disclosure of detailed information about business combination [line items] | |
Schedule of business combination | Fair values $m Intangible assets 1,326 Cash and cash equivalents 30 Current investments 87 Net deferred tax liability (246) Other immaterial balances 51 Total net assets acquired 1,248 Goodwill 947 Consideration 2,195 |
H1 2024 - Product Sales year-_2
H1 2024 - Product Sales year-on-year analysis (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
H1 2024 - Product Sales year-on-year analysis | |
H1 2024 Product Sales year-on-year analysis | World US Emerging Markets Europe Established RoW $m Act % chg CER % chg $m % chg $m Act % chg CER % chg $m Act % chg CER % chg $m Act % chg CER % chg Oncology 9,737 17 21 4,387 20 2,300 18 28 1,967 25 23 1,083 (2) 8 Tagrisso 3,203 10 13 1,282 16 919 8 16 628 16 15 374 (11) (2) Imfinzi 2,259 20 25 1,202 17 245 35 58 459 38 36 353 7 19 Calquence 1,508 27 28 1,048 21 75 82 n/m 320 42 41 65 30 34 Lynparza 1,450 6 9 607 5 320 15 26 398 9 8 125 (14) (6) Enhertu 249 n/m n/m - - 161 n/m n/m 57 n/m n/m 31 n/m n/m Zoladex 549 19 27 8 20 415 22 31 77 16 14 49 2 12 Imjudo 136 35 38 88 30 7 n/m n/m 16 n/m n/m 25 (5) 6 Truqap 142 n/m n/m 141 n/m - - - - - - 1 n/m n/m Orpathys 25 14 19 - - 25 14 19 - - - - - - Others 216 (21) (15) 11 6 133 (21) (15) 12 (36) (36) 60 (21) (12) BioPharmaceuticals: CVRM 6,164 18 22 1,483 16 2,749 17 24 1,559 33 32 373 (8) 2 Farxiga 3,785 35 38 867 37 1,474 37 44 1,233 45 44 211 (15) (5) Brilinta 665 - 2 354 (1) 166 4 14 136 - (1) 9 (26) (19) Crestor 589 1 6 22 (18) 475 4 9 22 (30) (29) 70 3 13 Seloken / Toprol-XL 315 (8) (1) - n/m 307 (8) (1) 6 4 7 2 (39) (37) Lokelma 249 26 30 115 10 42 75 83 41 62 61 51 16 31 roxadustat 163 22 27 - - 163 22 27 - - - - n/m n/m Andexxa 105 18 21 42 14 2 n/m n/m 40 38 36 21 (9) 4 Wainua 21 n/m n/m 21 n/m - - - - - - - - - Others 272 (30) (28) 62 (50) 120 (27) (22) 81 (10) (10) 9 (7) (5) BioPharmaceuticals: R&I 3,601 17 20 1,567 21 1,032 16 23 680 17 16 322 7 12 Symbicort 1,491 16 19 598 38 450 11 21 286 - (1) 157 (4) (2) Fasenra 781 5 6 478 2 41 45 53 192 9 8 70 (2) 6 Pulmicort 379 10 14 8 (53) 317 16 22 37 1 (1) 17 (13) (9) Breztri 454 48 51 225 37 131 61 69 65 80 79 33 33 44 Tezspire 100 n/m n/m - - 5 n/m n/m 61 n/m n/m 34 n/m n/m Saphnelo 203 77 77 184 71 2 n/m n/m 10 n/m n/m 7 86 91 Airsupra 21 n/m n/m 21 n/m - - - - - - - - - Others 172 (27) (26) 53 (47) 86 (18) (14) 29 3 2 4 (12) (10) BioPharmaceuticals: V&I 324 (27) (24) 55 n/m 131 (12) (7) 81 (28) (30) 57 (68) (65) Synagis 253 (11) (6) (1) n/m 131 4 10 67 (27) (29) 56 (15) (6) Beyfortus 54 n/m n/m 53 n/m - - - - (81) (61) 1 n/m n/m FluMist 8 n/m n/m 3 n/m - - - 5 n/m 97 - n/m n/m COVID-19 mAbs 3 (98) (98) - - - n/m n/m 3 (58) (59) - n/m n/m Others 6 (79) (80) - - - n/m n/m 6 (41) (43) - n/m n/m Rare Disease 4,243 11 15 2,517 10 454 40 70 794 3 2 478 9 20 Ultomiris 1,804 32 35 1,032 27 66 n/m n/m 411 32 31 295 42 58 Soliris 1,439 (13) (8) 808 (9) 255 19 54 260 (29) (30) 116 (33) (30) Strensiq 653 16 18 529 17 31 30 47 48 14 12 45 4 15 Koselugo 247 55 64 101 13 83 n/m n/m 45 95 92 18 n/m n/m Kanuma 100 17 20 47 18 19 7 20 30 24 25 4 11 20 Other medicines 560 (9) (2) 52 (24) 385 (1) 8 53 10 10 70 (35) (29) Nexium 459 (7) 1 47 (22) 318 4 15 26 3 2 68 (34) (28) Others 101 (17) (14) 5 (40) 67 (22) (18) 27 18 19 2 (53) (49) Total Product Sales 24,629 15 18 10,061 17 7,051 16 26 5,134 21 19 2,383 (6) 3 15 The table provides an analysis of year-on-year Product Sales, with Actual and CER growth rates reflecting year-on-year growth. Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. |
Q4 2023 Product Sales year-on-y
Q4 2023 Product Sales year-on-year analysis (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Q2 2024 Product Sales year-on-year analysis | |
Q2 2024 Product Sales year-on-year analysis | World US Emerging Markets Europe Established RoW $m Act % chg CER % chg $m % chg $m Act % chg CER % chg $m Act % chg CER % chg $m Act % chg CER % chg Oncology 4,976 14 18 2,302 17 1,098 11 22 1,015 24 24 561 (9) 2 Tagrisso 1,608 8 12 658 13 432 6 15 327 15 15 191 (12) (1) Imfinzi 1,147 13 18 620 15 117 16 39 227 33 33 183 (9) 3 Calquence 790 21 22 554 14 36 51 72 167 42 43 33 20 23 Lynparza 744 4 7 319 3 153 8 18 206 10 11 66 (15) (6) Enhertu 127 89 99 - - 77 60 72 31 n/m n/m 19 n/m n/m Zoladex 273 17 25 5 29 201 17 28 42 23 21 25 6 17 Imjudo 74 17 19 49 37 4 n/m n/m 8 64 55 13 (38) (30) Truqap 92 n/m n/m 91 n/m - - - - - - 1 n/m n/m Orpathys 12 (7) (3) - - 12 (7) (3) - - - - - - Others 109 (17) (11) 6 24 66 (16) (10) 7 (11) (10) 30 (26) (16) BioPharmaceuticals: CVRM 3,153 18 22 735 11 1,384 17 24 843 38 38 191 (14) (3) Farxiga 1,940 29 32 394 16 763 32 39 680 49 49 103 (23) (14) Brilinta 342 3 5 191 7 78 (1) 6 69 1 1 4 (38) (23) Crestor 292 4 11 12 (2) 234 8 14 10 (34) (32) 36 3 15 Seloken / Toprol-XL 150 (8) - - n/m 146 (8) - 3 46 53 1 (40) (38) Lokelma 136 36 41 64 29 21 68 78 23 63 64 28 16 33 roxadustat 88 20 26 - - 88 20 26 - - - - - - Andexxa 59 29 35 22 34 1 n/m n/m 22 51 51 14 (6) 8 Wainua 16 n/m n/m 16 n/m - - - - - - - - - Others 130 (26) (24) 36 (45) 53 (19) (14) 36 (9) (8) 5 (14) (12) BioPharmaceuticals: R&I 1,797 21 24 830 23 444 23 34 350 21 21 173 8 14 Symbicort 722 20 25 299 49 197 12 25 143 4 5 83 (4) (1) Fasenra 423 4 5 268 - 19 33 46 99 11 11 37 3 11 Pulmicort 155 25 30 3 (53) 126 40 47 17 6 2 9 (18) (13) Breztri 235 44 47 120 43 61 42 49 35 68 69 19 26 37 Tezspire 57 n/m n/m - - 3 n/m n/m 35 n/m n/m 19 n/m n/m Saphnelo 112 65 65 101 59 1 28 n/m 6 n/m n/m 4 90 86 Airsupra 14 n/m n/m 14 n/m - - - - - - - - - Others 79 (24) (22) 25 (52) 37 7 12 15 2 3 2 (6) (4) BioPharmaceuticals: V&I 112 28 42 28 n/m 41 (10) 4 7 (55) (53) 36 36 55 Synagis 81 (6) 8 (1) n/m 41 (16) (2) 6 (42) (42) 35 27 46 Beyfortus 28 n/m n/m 27 n/m - - - - n/m (91) 1 n/m n/m FluMist 2 n/m n/m 2 n/m - - - - (26) (21) - - - COVID-19 mAbs 1 n/m n/m - - - n/m n/m 1 (65) (64) - (99) (99) Others - n/m n/m - - - - - - n/m n/m - - - Rare Disease 2,147 10 14 1,311 10 203 35 67 392 3 3 241 7 18 Ultomiris 946 33 36 550 27 35 n/m n/m 209 38 38 152 38 56 Soliris 700 (14) (8) 398 (11) 129 30 74 118 (36) (36) 55 (36) (33) Strensiq 340 13 14 283 14 10 7 15 24 13 13 23 4 17 Koselugo 114 43 45 55 13 24 73 80 26 n/m n/m 9 63 85 Kanuma 47 3 8 25 21 5 (54) (49) 15 28 33 2 11 41 Other medicines 267 (11) (5) 28 (13) 179 (3) 5 24 (7) (7) 36 (38) (32) Nexium 219 (12) (5) 25 (17) 146 (2) 7 13 (5) (5) 35 (37) (32) Others 48 (9) (6) 3 39 33 (8) (4) 11 (9) (9) 1 (54) (49) Total Product Sales 12,452 14 18 5,234 16 3,349 15 25 2,631 23 23 1,238 (5) 5 16 The table provides an analysis of year-on-year Product Sales, with Actual and CER growth rates reflecting year-on-year growth. Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. |
Alliance Revenue (Tables)
Alliance Revenue (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Alliance revenue [Abstract] | |
Schedule of alliance revenue | H1 2024 H1 2023 $m $m Enhertu 683 475 Tezspire 180 105 Beyfortus 26 - Other Alliance Revenue 50 47 Total 939 627 |
Collaboration Revenue (Tables)
Collaboration Revenue (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Collaboration Revenue. | |
Schedule of collaboration revenue | H1 2024 H1 2023 $m $m Farxiga 49 25 COVID-19 mAbs: licence fees - 180 Other Collaboration Revenue - 15 Total 49 220 |
Other operating income and ex_2
Other operating income and expense (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Other operating income and expense | |
Schedule of other operating income and expense | H1 2024 H1 2023 $m $m brazikumab licence termination funding - 75 Divestment of US rights to Pulmicort Flexhaler - 241 Update to the contractual relationships for Beyfortus (nirsevimab) - 712 Other 127 135 Total 127 1,163 |
Basis of preparation and acco_3
Basis of preparation and accounting policies (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | |||||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | Dec. 31, 2023 | |||
Disclosure of detailed information about borrowings [line items] | |||||||
Alliance revenue | $ 482 | [1] | $ 341 | $ 939 | $ 627 | ||
Borrowings | 33,533 | 33,533 | $ 28,622 | ||||
Going concern | |||||||
Financial resources | 11,800 | 11,800 | |||||
Cash and cash equivalents | 6,916 | [2] | $ 5,664 | 6,916 | [2] | $ 5,664 | $ 5,840 |
February 2025 | |||||||
Going concern | |||||||
Undrawn committed bank facilities | 2,000 | 2,000 | |||||
April 2029 | |||||||
Going concern | |||||||
Undrawn committed bank facilities | 4,900 | 4,900 | |||||
Due within one year | |||||||
Disclosure of detailed information about borrowings [line items] | |||||||
Borrowings | $ 5,400 | $ 5,400 | |||||
[1] The Q2 2024 and Q2 2023 information in respect of the three months ended 30 June 2024 and 30 June 2023 respectively included in the Interim financial statements have not been reviewed by PricewaterhouseCoopers LLP. The Condensed consolidated statement of financial position as at 30 June 2024 and 30 June 2023 have been reviewed by PricewaterhouseCoopers LLP. The Condensed consolidated statement of financial position as at 31 December 2023 has been audited by PricewaterhouseCoopers LLP. |
Intangible assets - Net impairm
Intangible assets - Net impairment charges (reversals) (Details) - USD ($) $ in Millions | 6 Months Ended | ||
Jun. 30, 2024 | Jun. 30, 2023 | Feb. 19, 2024 | |
Impairment of intangible assets | |||
Payment for intangible assets | $ 1,474 | $ 1,436 | |
Icosavax, Inc | |||
Impairment of intangible assets | |||
Acquisition date fair value of consideration transferred, asset acquisition | $ 841 | ||
Intangible assets acquired | 639 | ||
Cash and cash equivalents acquired | 141 | ||
Marketable securities acquired | 51 | ||
Contingent consideration liabilities recognised in asset acquisition | $ 300 | ||
Intangible assets other than goodwill | |||
Impairment of intangible assets | |||
Impairment loss (reversal of impairment loss) | $ 26 | 320 | |
ALXN1840 | |||
Impairment of intangible assets | |||
Impairment loss (reversal of impairment loss) | $ 244 |
Net Debt (Details)
Net Debt (Details) - USD ($) $ in Millions | 6 Months Ended | ||
Jun. 30, 2024 | Dec. 31, 2023 | ||
Interest bearing loans and borrowings | |||
Non-current installments of loans at beginning of period | $ (22,365) | ||
Non-current instalments of loans - Cash Flow | (4,973) | ||
Non-current instalments of loans - Acquisitions | (3) | ||
Non-current installments of loans - Non-cash & Other | (2) | ||
Non-current installments of loans - Exchange Movements | 118 | ||
Non-current installments of loans at end of period | [1] | (27,225) | |
Non-current installments of leases at beginning of period | (857) | ||
Non-current instalments of leases - Acquisitions | (12) | ||
Non-current installments of leases - Non-cash & Other | (97) | ||
Non-current installments of leases - Exchange Movements | 17 | ||
Non-current installments of leases at end of period | [1] | (949) | |
Total long-term debt at beginning of period | (23,222) | ||
Total long-term debt - Cash Flow | (4,973) | ||
Total long-term debt - Non-cash & Other | (99) | ||
Total long-term debt - Acquisitions | (15) | ||
Total long-term debt - Exchange Movements | 135 | ||
Total long-term debt at end of period | (28,174) | ||
Current instalments of loans at beginning of period | (4,614) | ||
Current instalments of loans - Cash Flow | 2,583 | ||
Current instalments of loans - Acquisitions | (9) | ||
Current instalments of loans - Non-cash & Other | (5) | ||
Current instalments of loans - Exchange Movements | 27 | ||
Current instalments of loans at end of period | (2,018) | ||
Current instalments of leases at beginning of period | (271) | ||
Current instalments of leases - Cash Flow | 174 | ||
Current instalments of leases - Acquisitions | (6) | ||
Current instalments of leases - Non-cash & Other | (197) | ||
Current instalments of leases - Exchange Movements | 8 | ||
Current instalments of leases at end of period | [1] | (292) | |
Interest-bearing loans and borrowings at beginning of period | (5,129) | ||
Interest-bearing loans and borrowings at end of period | [1] | (5,067) | |
Total current debt at beginning of period | (5,400) | ||
Total current debt - Cash Flow | 219 | ||
Total current debt - Acquisitions | (15) | ||
Total current debt - Non-cash & Other | (202) | ||
Total current debt - Exchange Movements | 39 | ||
Total current debt at end of period | (5,359) | ||
Gross borrowings at beginning of period | (28,622) | ||
Gross borrowings - Cash Flow | (4,754) | ||
Gross borrowings - Acquisitions | (30) | ||
Gross borrowings - Non-cash & Other | (301) | ||
Gross borrowings - Exchange Movements | 174 | ||
Gross borrowings at end of period | (33,533) | ||
Net derivative financial instruments at beginning of period | 150 | ||
Net derivative financial instruments - Cash Flow | 65 | ||
Net derivative financial instruments - Non-cash & Other | (82) | ||
Net derivative financial instruments at end of period | 133 | ||
Net borrowings at beginning of period | (28,472) | ||
Net borrowings - Cash Flow | (4,689) | ||
Net borrowings - Acquisitions | (30) | ||
Net borrowings - Non-cash & Other | (383) | ||
Net borrowings - Exchange Movements | 174 | ||
Net borrowings at end of period | (33,400) | ||
Cash and cash equivalents at the beginning of the period | 5,840 | ||
Cash and cash equivalents - Cash Flow | 885 | ||
Cash and cash equivalents - Acquisitions | 242 | ||
Cash and cash equivalents - Exchange Movements | (51) | ||
Cash and cash equivalents at the end of the period | [1] | 6,916 | |
Other investments - current at beginning of period | 122 | ||
Other investments, current - Cash Flow | (42) | ||
Other investments - current - Acquisitions | 87 | ||
Other investments, current - Exchange Movements | (7) | ||
Other investments - current at end of period | [1] | 160 | |
Cash and investments at beginning of period | 5,962 | ||
Cash and investments - Cash Flow | 843 | ||
Cash and investments - Acquisitions | 329 | ||
Cash and investments - Exchange Movements | (58) | ||
Cash and investments at end of period | 7,076 | ||
Net debt at beginning of period | (22,510) | ||
Net debt - Cash Flow | (3,846) | ||
Net debt - Acquisitions | 299 | ||
Net debt - Non-cash & Other | (383) | ||
Net debt - Exchange Movements | 116 | ||
Net debt at end of period | (26,324) | ||
Cash collateral on financial derivatives | 202 | $ 215 | |
Cash collateral posted by the Group | 97 | 102 | |
Increase (decrease) in net debt | 3,814 | ||
Acerta Pharma | |||
Interest bearing loans and borrowings | |||
Share purchase liability | 0 | $ 833 | |
Commercial paper | |||
Interest bearing loans and borrowings | |||
Current borrowings and current portion of non-current borrowing - Cash Flow | (2,453) | ||
Interest-bearing loans and borrowings at end of period | (2,453) | ||
Collateral received from derivative counterparties | |||
Interest bearing loans and borrowings | |||
Interest-bearing loans and borrowings at beginning of period | (215) | ||
Current borrowings and current portion of non-current borrowing - Cash Flow | 13 | ||
Interest-bearing loans and borrowings at end of period | (202) | ||
Other Short-term borrowings excluding overdrafts | |||
Interest bearing loans and borrowings | |||
Interest-bearing loans and borrowings at beginning of period | (97) | ||
Current borrowings and current portion of non-current borrowing - Cash Flow | (63) | ||
Current borrowings and current portion of non-current borrowing - Exchange Movements | 5 | ||
Interest-bearing loans and borrowings at end of period | (155) | ||
Overdrafts | |||
Interest bearing loans and borrowings | |||
Interest-bearing loans and borrowings at beginning of period | (203) | ||
Current borrowings and current portion of non-current borrowing - Cash Flow | (35) | ||
Current borrowings and current portion of non-current borrowing - Exchange Movements | (1) | ||
Interest-bearing loans and borrowings at end of period | $ (239) | ||
[1] The Condensed consolidated statement of financial position as at 30 June 2024 and 30 June 2023 have been reviewed by PricewaterhouseCoopers LLP. The Condensed consolidated statement of financial position as at 31 December 2023 has been audited by PricewaterhouseCoopers LLP. |
Net Debt - Narrative disclosure
Net Debt - Narrative disclosures (Details) $ in Millions | 1 Months Ended | 3 Months Ended | 6 Months Ended | |
Feb. 29, 2024 USD ($) | Jun. 30, 2024 USD ($) | Jun. 30, 2024 USD ($) | Jun. 30, 2023 USD ($) | |
Disclosure of detailed information about borrowings [line items] | ||||
Number of bonds repaid | 2 | |||
Repayment of bonds | $ 2,569 | |||
Repayment of loans and borrowings | 2,643 | $ 2,643 | $ 3,408 | |
Fixed-rate notes maturing February 2027 | ||||
Disclosure of detailed information about borrowings [line items] | ||||
Issue of fixed-rate notes | $ 1,250 | |||
Borrowings, interest rate | 4.80% | |||
Fixed-rate notes maturing February 2029 | ||||
Disclosure of detailed information about borrowings [line items] | ||||
Issue of fixed-rate notes | $ 1,250 | |||
Borrowings, interest rate | 4.85% | |||
Fixed-rate notes maturing February 2031 | ||||
Disclosure of detailed information about borrowings [line items] | ||||
Issue of fixed-rate notes | $ 1,000 | |||
Borrowings, interest rate | 4.90% | |||
Fixed-rate notes maturing February 2034 | ||||
Disclosure of detailed information about borrowings [line items] | ||||
Issue of fixed-rate notes | $ 1,500 | |||
Borrowings, interest rate | 5% | |||
Commercial paper issued in 2024 | ||||
Disclosure of detailed information about borrowings [line items] | ||||
Commercial papers, value | $ 2,453 | $ 2,453 | $ 0 |
Financial instruments (Details)
Financial instruments (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | Dec. 31, 2023 | ||
Financial instruments fair value gains | ||||||
Net gains/(losses) on equity investments measured at fair value through other comprehensive income | $ 54 | [1] | $ (94) | $ 89 | $ (48) | |
Non-cash and other movements | (550) | (594) | ||||
Net cash inflow from operating activities | 5,571 | 4,851 | ||||
Reconciliation of changes in contingent liabilities in business combination | ||||||
Contingent liabilities recognised in business combination at beginning of period | 2,137 | 2,222 | ||||
Additions | 198 | 60 | ||||
Settlements | (474) | (398) | ||||
Revaluations | 251 | 202 | ||||
Discount unwind | 57 | 66 | ||||
Contingent liabilities recognised in business combination at end of period | 2,169 | $ 2,152 | 2,169 | 2,152 | ||
Diabetes alliance | ||||||
Reconciliation of changes in contingent liabilities in business combination | ||||||
Contingent liabilities recognised in business combination at beginning of period | 1,945 | |||||
Settlements | (473) | |||||
Revaluations | 220 | |||||
Discount unwind | 50 | |||||
Contingent liabilities recognised in business combination at end of period | 1,742 | 1,742 | ||||
Increase/decrease in contingent consideration balance with change in current estimates | $ 174 | 174 | ||||
Percentage of reasonably possible increase or decrease in sales estimates | 10% | |||||
Other | ||||||
Reconciliation of changes in contingent liabilities in business combination | ||||||
Contingent liabilities recognised in business combination at beginning of period | 192 | |||||
Additions | 198 | |||||
Settlements | (1) | |||||
Revaluations | 31 | |||||
Discount unwind | 7 | |||||
Contingent liabilities recognised in business combination at end of period | $ 427 | 427 | ||||
Interest-Bearing Loans and Borrowings | Not measured at fair value in statement of financial position but for which fair value is disclosed | ||||||
Financial instruments fair value gains | ||||||
Carrying value, financial liabilities | 33,533 | 33,533 | ||||
Financial liabilities, at fair value | 32,231 | 32,231 | ||||
Financial assets at amortised cost | ||||||
Financial instruments fair value gains | ||||||
Cash collateral pledged to counterparties | 97 | 97 | ||||
Other Investments | Financial assets measured at fair value | ||||||
Financial instruments fair value gains | ||||||
Financial assets. | 1,670 | 1,670 | ||||
Money market funds | Financial assets measured at fair value | ||||||
Financial instruments fair value gains | ||||||
Financial assets. | 5,463 | 5,463 | ||||
Derivatives | Financial assets measured at fair value | ||||||
Financial instruments fair value gains | ||||||
Financial assets. | 133 | 133 | ||||
Level 3 | ||||||
Financial instruments fair value gains | ||||||
Net gains/(losses) on equity investments measured at fair value through other comprehensive income | 1 | $ 1 | ||||
Level 3 | Equity investments | ||||||
Financial instruments fair value gains | ||||||
Financial assets. | 337 | 337 | $ 313 | |||
Level 3 | Equity investments | Financial assets measured at fair value | ||||||
Financial instruments fair value gains | ||||||
Financial assets. | $ 350 | $ 350 | ||||
[1] The Q2 2024 and Q2 2023 information in respect of the three months ended 30 June 2024 and 30 June 2023 respectively included in the Interim financial statements have not been reviewed by PricewaterhouseCoopers LLP. |
Business combinations - Gracell
Business combinations - Gracell (Details) - Gracell Biotechnologies Inc. $ in Millions | Feb. 22, 2024 USD ($) |
Disclosure of detailed information about business combination [line items] | |
Contingent consideration | $ 54 |
Cash transferred | 983 |
Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [abstract] | |
Intangible assets | 1,038 |
Cash and cash equivalents | 212 |
Net deferred tax liability | (260) |
Other immaterial balances | (89) |
Total net assets acquired | 901 |
Goodwill | 136 |
Consideration | $ 1,037 |
Business Combinations - Fusion
Business Combinations - Fusion (Details) - Fusion Pharmaceuticals Inc. $ in Millions | Jun. 04, 2024 USD ($) |
Disclosure of detailed information about business combination [line items] | |
Cash transferred | $ 2,051 |
Contingent consideration | $ 144 |
Percentage of ownership interest in acquiree held immediately prior to business combination | 1% |
Acquisition-date fair value of equity interest in acquiree held by acquirer immediately before acquisition date | $ 24 |
Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [abstract] | |
Intangible assets | 1,326 |
Cash and cash equivalents | 30 |
Current investments | 87 |
Net deferred tax liability | (246) |
Other immaterial balances | 51 |
Total net assets acquired | 1,248 |
Goodwill | 947 |
Consideration | 2,195 |
FPI-2265 programme | |
Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [abstract] | |
Intangible assets | 848 |
FPI-2059 programme | |
Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [abstract] | |
Intangible assets | 165 |
AZD2068 programme | |
Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [abstract] | |
Intangible assets | $ 313 |
Legal proceedings and conting_2
Legal proceedings and contingent liabilities - Legal proceedings (Details) $ in Thousands | 1 Months Ended | 2 Months Ended | 6 Months Ended | 12 Months Ended | 36 Months Ended | ||||||||
May 31, 2024 USD ($) | Dec. 31, 2023 USD ($) | Dec. 31, 2022 employee | Jul. 31, 2020 USD ($) | Aug. 31, 2017 lawsuit | Jun. 30, 2024 | Dec. 31, 2021 lawsuit | Dec. 31, 2019 lawsuit | Dec. 31, 2021 lawsuit | Jan. 31, 2024 patent | Oct. 31, 2023 USD ($) | Apr. 30, 2022 USD ($) | Oct. 31, 2012 agreement patent | |
Soliris patent proceedings | |||||||||||||
Commitments and contingent liabilities | |||||||||||||
Number of patents involved in patent proceedings | patent | 6 | ||||||||||||
Number of patents involved in proceedings that are subject to inter partes review | patent | 5 | ||||||||||||
PARP Inhibitor Royalty Dispute | |||||||||||||
Commitments and contingent liabilities | |||||||||||||
Number of disputed royalty-bearing patent license agreements | agreement | 2 | ||||||||||||
Calquence US Patent proceedings | |||||||||||||
Commitments and contingent liabilities | |||||||||||||
Number of generic manufacturers which settlement agreements have been entered with | 5 | ||||||||||||
Number of generic manufacturers with which proceedings are ongoing | 3 | ||||||||||||
Lokelma US patent proceedings | |||||||||||||
Commitments and contingent liabilities | |||||||||||||
Number of generic manufacturers which settlement agreements have been entered with | 2 | ||||||||||||
Nexium and LosecPrilosec US proceedings | |||||||||||||
Commitments and contingent liabilities | |||||||||||||
Legal proceedings provision | $ 425,000 | ||||||||||||
Nexium and LosecPrilosec Canada proceedings | |||||||||||||
Commitments and contingent liabilities | |||||||||||||
Number of class action lawsuits brought against entity | lawsuit | 3 | ||||||||||||
Number of class action lawsuits dismissed | lawsuit | 1 | 1 | 2 | ||||||||||
Commencement of major litigation | Soliris patent proceedings | |||||||||||||
Commitments and contingent liabilities | |||||||||||||
Number of patents involved in patent proceedings | patent | 6 | ||||||||||||
Number of patents involved in proceedings that are subject to inter partes review | patent | 5 | ||||||||||||
Daiichi Sankyo | Enhertu US patent proceedings | |||||||||||||
Commitments and contingent liabilities | |||||||||||||
Damages payable | $ 41,820 | ||||||||||||
Royalties payable on sales, percent | 8% | ||||||||||||
PARP Inhibitor Royalty Dispute | |||||||||||||
Commitments and contingent liabilities | |||||||||||||
Number of disputed royalty-bearing patent license agreements | patent | 2 | ||||||||||||
Pay Equity Litigation | |||||||||||||
Commitments and contingent liabilities | |||||||||||||
Number of plaintiffs in case | 3 | ||||||||||||
Tagrisso US patent proceedings | |||||||||||||
Commitments and contingent liabilities | |||||||||||||
Litigation settlement, amount awarded to counterparty | $ 107,500 | ||||||||||||
Turkish Ministry of Health matter | Alexion Turkey | |||||||||||||
Commitments and contingent liabilities | |||||||||||||
Amount of civil settlements disclosed in case | $ 21,500 | ||||||||||||
Definiens commercial litigation | |||||||||||||
Commitments and contingent liabilities | |||||||||||||
Amount of claims against entity | $ 140,000 | ||||||||||||
Litigation settlement, amount awarded to counterparty | $ 46,430 | ||||||||||||
US employment litigation | |||||||||||||
Commitments and contingent liabilities | |||||||||||||
Number of former employees that filed lawsuit for disparate treatment | employee | 7 |
Subsequent Events (Details)
Subsequent Events (Details) - Major business combination - Amolyt Pharma $ in Millions | Jul. 15, 2024 USD ($) |
Subsequent events | |
Total fair value of consideration | $ 1,050 |
Upfront payment | 800 |
Contingent consideration | $ 250 |
H1 2024 - Product Sales year-_3
H1 2024 - Product Sales year-on-year analysis (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | ||
Product sales | |||||
Product Sales | $ 12,452 | [1] | $ 10,882 | $ 24,629 | $ 21,448 |
Actual %, year-on-year | 14% | 15% | |||
CER %, year-on-year | 18% | 18% | |||
US | |||||
Product sales | |||||
Product Sales | $ 5,234 | $ 10,061 | |||
Actual %, year-on-year | 16% | 17% | |||
Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 3,349 | $ 7,051 | |||
Actual %, year-on-year | 15% | 16% | |||
CER %, year-on-year | 25% | 26% | |||
Europe | |||||
Product sales | |||||
Product Sales | $ 2,631 | $ 5,134 | |||
Actual %, year-on-year | 23% | 21% | |||
CER %, year-on-year | 23% | 19% | |||
Established ROW | |||||
Product sales | |||||
Product Sales | $ 1,238 | $ 2,383 | |||
Actual %, year-on-year | (5.00%) | (6.00%) | |||
CER %, year-on-year | 5% | 3% | |||
Total Oncology | |||||
Product sales | |||||
Product Sales | $ 4,976 | $ 9,737 | |||
Actual %, year-on-year | 14% | 17% | |||
CER %, year-on-year | 18% | 21% | |||
Total Oncology | US | |||||
Product sales | |||||
Product Sales | $ 2,302 | $ 4,387 | |||
Actual %, year-on-year | 17% | 20% | |||
Total Oncology | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 1,098 | $ 2,300 | |||
Actual %, year-on-year | 11% | 18% | |||
CER %, year-on-year | 22% | 28% | |||
Total Oncology | Europe | |||||
Product sales | |||||
Product Sales | $ 1,015 | $ 1,967 | |||
Actual %, year-on-year | 24% | 25% | |||
CER %, year-on-year | 24% | 23% | |||
Total Oncology | Established ROW | |||||
Product sales | |||||
Product Sales | $ 561 | $ 1,083 | |||
Actual %, year-on-year | (9.00%) | (2.00%) | |||
CER %, year-on-year | 2% | 8% | |||
Tagrisso | |||||
Product sales | |||||
Product Sales | $ 1,608 | $ 3,203 | |||
Actual %, year-on-year | 8% | 10% | |||
CER %, year-on-year | 12% | 13% | |||
Tagrisso | US | |||||
Product sales | |||||
Product Sales | $ 658 | $ 1,282 | |||
Actual %, year-on-year | 13% | 16% | |||
Tagrisso | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 432 | $ 919 | |||
Actual %, year-on-year | 6% | 8% | |||
CER %, year-on-year | 15% | 16% | |||
Tagrisso | Europe | |||||
Product sales | |||||
Product Sales | $ 327 | $ 628 | |||
Actual %, year-on-year | 15% | 16% | |||
CER %, year-on-year | 15% | 15% | |||
Tagrisso | Established ROW | |||||
Product sales | |||||
Product Sales | $ 191 | $ 374 | |||
Actual %, year-on-year | (12.00%) | (11.00%) | |||
CER %, year-on-year | (1.00%) | (2.00%) | |||
Imfinzi | |||||
Product sales | |||||
Product Sales | $ 1,147 | $ 2,259 | |||
Actual %, year-on-year | 13% | 20% | |||
CER %, year-on-year | 18% | 25% | |||
Imfinzi | US | |||||
Product sales | |||||
Product Sales | $ 620 | $ 1,202 | |||
Actual %, year-on-year | 15% | 17% | |||
Imfinzi | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 117 | $ 245 | |||
Actual %, year-on-year | 16% | 35% | |||
CER %, year-on-year | 39% | 58% | |||
Imfinzi | Europe | |||||
Product sales | |||||
Product Sales | $ 227 | $ 459 | |||
Actual %, year-on-year | 33% | 38% | |||
CER %, year-on-year | 33% | 36% | |||
Imfinzi | Established ROW | |||||
Product sales | |||||
Product Sales | $ 183 | $ 353 | |||
Actual %, year-on-year | (9.00%) | 7% | |||
CER %, year-on-year | 3% | 19% | |||
Calquence | |||||
Product sales | |||||
Product Sales | $ 790 | $ 1,508 | |||
Actual %, year-on-year | 21% | 27% | |||
CER %, year-on-year | 22% | 28% | |||
Calquence | US | |||||
Product sales | |||||
Product Sales | $ 554 | $ 1,048 | |||
Actual %, year-on-year | 14% | 21% | |||
Calquence | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 36 | $ 75 | |||
Actual %, year-on-year | 51% | 82% | |||
CER %, year-on-year | 72% | ||||
Calquence | Europe | |||||
Product sales | |||||
Product Sales | $ 167 | $ 320 | |||
Actual %, year-on-year | 42% | 42% | |||
CER %, year-on-year | 43% | 41% | |||
Calquence | Established ROW | |||||
Product sales | |||||
Product Sales | $ 33 | $ 65 | |||
Actual %, year-on-year | 20% | 30% | |||
CER %, year-on-year | 23% | 34% | |||
Lynparza | |||||
Product sales | |||||
Product Sales | $ 744 | $ 1,450 | |||
Actual %, year-on-year | 4% | 6% | |||
CER %, year-on-year | 7% | 9% | |||
Lynparza | US | |||||
Product sales | |||||
Product Sales | $ 319 | $ 607 | |||
Actual %, year-on-year | 3% | 5% | |||
Lynparza | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 153 | $ 320 | |||
Actual %, year-on-year | 8% | 15% | |||
CER %, year-on-year | 18% | 26% | |||
Lynparza | Europe | |||||
Product sales | |||||
Product Sales | $ 206 | $ 398 | |||
Actual %, year-on-year | 10% | 9% | |||
CER %, year-on-year | 11% | 8% | |||
Lynparza | Established ROW | |||||
Product sales | |||||
Product Sales | $ 66 | $ 125 | |||
Actual %, year-on-year | (15.00%) | (14.00%) | |||
CER %, year-on-year | (6.00%) | (6.00%) | |||
Enhertu | |||||
Product sales | |||||
Product Sales | $ 127 | $ 249 | |||
Actual %, year-on-year | 89% | ||||
CER %, year-on-year | 99% | ||||
Enhertu | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 77 | 161 | |||
Actual %, year-on-year | 60% | ||||
CER %, year-on-year | 72% | ||||
Enhertu | Europe | |||||
Product sales | |||||
Product Sales | $ 31 | 57 | |||
Enhertu | Established ROW | |||||
Product sales | |||||
Product Sales | 19 | 31 | |||
Zoladex | |||||
Product sales | |||||
Product Sales | $ 273 | $ 549 | |||
Actual %, year-on-year | 17% | 19% | |||
CER %, year-on-year | 25% | 27% | |||
Zoladex | US | |||||
Product sales | |||||
Product Sales | $ 5 | $ 8 | |||
Actual %, year-on-year | 29% | 20% | |||
Zoladex | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 201 | $ 415 | |||
Actual %, year-on-year | 17% | 22% | |||
CER %, year-on-year | 28% | 31% | |||
Zoladex | Europe | |||||
Product sales | |||||
Product Sales | $ 42 | $ 77 | |||
Actual %, year-on-year | 23% | 16% | |||
CER %, year-on-year | 21% | 14% | |||
Zoladex | Established ROW | |||||
Product sales | |||||
Product Sales | $ 25 | $ 49 | |||
Actual %, year-on-year | 6% | 2% | |||
CER %, year-on-year | 17% | 12% | |||
Imjudo | |||||
Product sales | |||||
Product Sales | $ 74 | $ 136 | |||
Actual %, year-on-year | 17% | 35% | |||
CER %, year-on-year | 19% | 38% | |||
Imjudo | US | |||||
Product sales | |||||
Product Sales | $ 49 | $ 88 | |||
Actual %, year-on-year | 37% | 30% | |||
Imjudo | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 4 | $ 7 | |||
Imjudo | Europe | |||||
Product sales | |||||
Product Sales | $ 8 | 16 | |||
Actual %, year-on-year | 64% | ||||
CER %, year-on-year | 55% | ||||
Imjudo | Established ROW | |||||
Product sales | |||||
Product Sales | $ 13 | $ 25 | |||
Actual %, year-on-year | (38.00%) | (5.00%) | |||
CER %, year-on-year | (30.00%) | 6% | |||
Truqap | |||||
Product sales | |||||
Product Sales | $ 92 | $ 142 | |||
Truqap | US | |||||
Product sales | |||||
Product Sales | 91 | 141 | |||
Truqap | Established ROW | |||||
Product sales | |||||
Product Sales | 1 | 1 | |||
Orpathys | |||||
Product sales | |||||
Product Sales | $ 12 | $ 25 | |||
Actual %, year-on-year | (7.00%) | 14% | |||
CER %, year-on-year | (3.00%) | 19% | |||
Orpathys | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 12 | $ 25 | |||
Actual %, year-on-year | (7.00%) | 14% | |||
CER %, year-on-year | (3.00%) | 19% | |||
Oncology, Others | |||||
Product sales | |||||
Product Sales | $ 109 | $ 216 | |||
Actual %, year-on-year | (17.00%) | (21.00%) | |||
CER %, year-on-year | (11.00%) | (15.00%) | |||
Oncology, Others | US | |||||
Product sales | |||||
Product Sales | $ 6 | $ 11 | |||
Actual %, year-on-year | 24% | 6% | |||
Oncology, Others | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 66 | $ 133 | |||
Actual %, year-on-year | (16.00%) | (21.00%) | |||
CER %, year-on-year | (10.00%) | (15.00%) | |||
Oncology, Others | Europe | |||||
Product sales | |||||
Product Sales | $ 7 | $ 12 | |||
Actual %, year-on-year | (11.00%) | (36.00%) | |||
CER %, year-on-year | (10.00%) | (36.00%) | |||
Oncology, Others | Established ROW | |||||
Product sales | |||||
Product Sales | $ 30 | $ 60 | |||
Actual %, year-on-year | (26.00%) | (21.00%) | |||
CER %, year-on-year | (16.00%) | (12.00%) | |||
BioPharmaceuticals: total CVRM | |||||
Product sales | |||||
Product Sales | $ 3,153 | $ 6,164 | |||
Actual %, year-on-year | 18% | 18% | |||
CER %, year-on-year | 22% | 22% | |||
BioPharmaceuticals: total CVRM | US | |||||
Product sales | |||||
Product Sales | $ 735 | $ 1,483 | |||
Actual %, year-on-year | 11% | 16% | |||
BioPharmaceuticals: total CVRM | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 1,384 | $ 2,749 | |||
Actual %, year-on-year | 17% | 17% | |||
CER %, year-on-year | 24% | 24% | |||
BioPharmaceuticals: total CVRM | Europe | |||||
Product sales | |||||
Product Sales | $ 843 | $ 1,559 | |||
Actual %, year-on-year | 38% | 33% | |||
CER %, year-on-year | 38% | 32% | |||
BioPharmaceuticals: total CVRM | Established ROW | |||||
Product sales | |||||
Product Sales | $ 191 | $ 373 | |||
Actual %, year-on-year | (14.00%) | (8.00%) | |||
CER %, year-on-year | (3.00%) | 2% | |||
Farxiga | |||||
Product sales | |||||
Product Sales | $ 1,940 | $ 3,785 | |||
Actual %, year-on-year | 29% | 35% | |||
CER %, year-on-year | 32% | 38% | |||
Farxiga | US | |||||
Product sales | |||||
Product Sales | $ 394 | $ 867 | |||
Actual %, year-on-year | 16% | 37% | |||
Farxiga | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 763 | $ 1,474 | |||
Actual %, year-on-year | 32% | 37% | |||
CER %, year-on-year | 39% | 44% | |||
Farxiga | Europe | |||||
Product sales | |||||
Product Sales | $ 680 | $ 1,233 | |||
Actual %, year-on-year | 49% | 45% | |||
CER %, year-on-year | 49% | 44% | |||
Farxiga | Established ROW | |||||
Product sales | |||||
Product Sales | $ 103 | $ 211 | |||
Actual %, year-on-year | (23.00%) | (15.00%) | |||
CER %, year-on-year | (14.00%) | (5.00%) | |||
Brilinta | |||||
Product sales | |||||
Product Sales | $ 342 | $ 665 | |||
Actual %, year-on-year | 3% | ||||
CER %, year-on-year | 5% | 2% | |||
Brilinta | US | |||||
Product sales | |||||
Product Sales | $ 191 | $ 354 | |||
Actual %, year-on-year | 7% | (1.00%) | |||
Brilinta | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 78 | $ 166 | |||
Actual %, year-on-year | (1.00%) | 4% | |||
CER %, year-on-year | 6% | 14% | |||
Brilinta | Europe | |||||
Product sales | |||||
Product Sales | $ 69 | $ 136 | |||
Actual %, year-on-year | 1% | ||||
CER %, year-on-year | 1% | (1.00%) | |||
Brilinta | Established ROW | |||||
Product sales | |||||
Product Sales | $ 4 | $ 9 | |||
Actual %, year-on-year | (38.00%) | (26.00%) | |||
CER %, year-on-year | (23.00%) | (19.00%) | |||
Crestor | |||||
Product sales | |||||
Product Sales | $ 292 | $ 589 | |||
Actual %, year-on-year | 4% | 1% | |||
CER %, year-on-year | 11% | 6% | |||
Crestor | US | |||||
Product sales | |||||
Product Sales | $ 12 | $ 22 | |||
Actual %, year-on-year | (2.00%) | (18.00%) | |||
Crestor | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 234 | $ 475 | |||
Actual %, year-on-year | 8% | 4% | |||
CER %, year-on-year | 14% | 9% | |||
Crestor | Europe | |||||
Product sales | |||||
Product Sales | $ 10 | $ 22 | |||
Actual %, year-on-year | (34.00%) | (30.00%) | |||
CER %, year-on-year | (32.00%) | (29.00%) | |||
Crestor | Established ROW | |||||
Product sales | |||||
Product Sales | $ 36 | $ 70 | |||
Actual %, year-on-year | 3% | 3% | |||
CER %, year-on-year | 15% | 13% | |||
Seloken/Toprol-XL | |||||
Product sales | |||||
Product Sales | $ 150 | $ 315 | |||
Actual %, year-on-year | (8.00%) | (8.00%) | |||
CER %, year-on-year | (1.00%) | ||||
Seloken/Toprol-XL | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 146 | $ 307 | |||
Actual %, year-on-year | (8.00%) | (8.00%) | |||
CER %, year-on-year | (1.00%) | ||||
Seloken/Toprol-XL | Europe | |||||
Product sales | |||||
Product Sales | $ 3 | $ 6 | |||
Actual %, year-on-year | 46% | 4% | |||
CER %, year-on-year | 53% | 7% | |||
Seloken/Toprol-XL | Established ROW | |||||
Product sales | |||||
Product Sales | $ 1 | $ 2 | |||
Actual %, year-on-year | (40.00%) | (39.00%) | |||
CER %, year-on-year | (38.00%) | (37.00%) | |||
Lokelma | |||||
Product sales | |||||
Product Sales | $ 136 | $ 249 | |||
Actual %, year-on-year | 36% | 26% | |||
CER %, year-on-year | 41% | 30% | |||
Lokelma | US | |||||
Product sales | |||||
Product Sales | $ 64 | $ 115 | |||
Actual %, year-on-year | 29% | 10% | |||
Lokelma | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 21 | $ 42 | |||
Actual %, year-on-year | 68% | 75% | |||
CER %, year-on-year | 78% | 83% | |||
Lokelma | Europe | |||||
Product sales | |||||
Product Sales | $ 23 | $ 41 | |||
Actual %, year-on-year | 63% | 62% | |||
CER %, year-on-year | 64% | 61% | |||
Lokelma | Established ROW | |||||
Product sales | |||||
Product Sales | $ 28 | $ 51 | |||
Actual %, year-on-year | 16% | 16% | |||
CER %, year-on-year | 33% | 31% | |||
roxadustat | |||||
Product sales | |||||
Product Sales | $ 88 | $ 163 | |||
Actual %, year-on-year | 20% | 22% | |||
CER %, year-on-year | 26% | 27% | |||
roxadustat | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 88 | $ 163 | |||
Actual %, year-on-year | 20% | 22% | |||
CER %, year-on-year | 26% | 27% | |||
Andexxa | |||||
Product sales | |||||
Product Sales | $ 59 | $ 105 | |||
Actual %, year-on-year | 29% | 18% | |||
CER %, year-on-year | 35% | 21% | |||
Andexxa | US | |||||
Product sales | |||||
Product Sales | $ 22 | $ 42 | |||
Actual %, year-on-year | 34% | 14% | |||
Andexxa | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 1 | $ 2 | |||
Andexxa | Europe | |||||
Product sales | |||||
Product Sales | $ 22 | $ 40 | |||
Actual %, year-on-year | 51% | 38% | |||
CER %, year-on-year | 51% | 36% | |||
Andexxa | Established ROW | |||||
Product sales | |||||
Product Sales | $ 14 | $ 21 | |||
Actual %, year-on-year | (6.00%) | (9.00%) | |||
CER %, year-on-year | 8% | 4% | |||
Wainua | |||||
Product sales | |||||
Product Sales | $ 16 | $ 21 | |||
Wainua | US | |||||
Product sales | |||||
Product Sales | 16 | 21 | |||
CVRM, Others | |||||
Product sales | |||||
Product Sales | $ 130 | $ 272 | |||
Actual %, year-on-year | (26.00%) | (30.00%) | |||
CER %, year-on-year | (24.00%) | (28.00%) | |||
CVRM, Others | US | |||||
Product sales | |||||
Product Sales | $ 36 | $ 62 | |||
Actual %, year-on-year | (45.00%) | (50.00%) | |||
CVRM, Others | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 53 | $ 120 | |||
Actual %, year-on-year | (19.00%) | (27.00%) | |||
CER %, year-on-year | (14.00%) | (22.00%) | |||
CVRM, Others | Europe | |||||
Product sales | |||||
Product Sales | $ 36 | $ 81 | |||
Actual %, year-on-year | (9.00%) | (10.00%) | |||
CER %, year-on-year | (8.00%) | (10.00%) | |||
CVRM, Others | Established ROW | |||||
Product sales | |||||
Product Sales | $ 5 | $ 9 | |||
Actual %, year-on-year | (14.00%) | (7.00%) | |||
CER %, year-on-year | (12.00%) | (5.00%) | |||
BioPharmaceuticals: total Respiratory & Immunology | |||||
Product sales | |||||
Product Sales | $ 1,797 | $ 3,601 | |||
Actual %, year-on-year | 21% | 17% | |||
CER %, year-on-year | 24% | 20% | |||
BioPharmaceuticals: total Respiratory & Immunology | US | |||||
Product sales | |||||
Product Sales | $ 830 | $ 1,567 | |||
Actual %, year-on-year | 23% | 21% | |||
BioPharmaceuticals: total Respiratory & Immunology | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 444 | $ 1,032 | |||
Actual %, year-on-year | 23% | 16% | |||
CER %, year-on-year | 34% | 23% | |||
BioPharmaceuticals: total Respiratory & Immunology | Europe | |||||
Product sales | |||||
Product Sales | $ 350 | $ 680 | |||
Actual %, year-on-year | 21% | 17% | |||
CER %, year-on-year | 21% | 16% | |||
BioPharmaceuticals: total Respiratory & Immunology | Established ROW | |||||
Product sales | |||||
Product Sales | $ 173 | $ 322 | |||
Actual %, year-on-year | 8% | 7% | |||
CER %, year-on-year | 14% | 12% | |||
Symbicort | |||||
Product sales | |||||
Product Sales | $ 722 | $ 1,491 | |||
Actual %, year-on-year | 20% | 16% | |||
CER %, year-on-year | 25% | 19% | |||
Symbicort | US | |||||
Product sales | |||||
Product Sales | $ 299 | $ 598 | |||
Actual %, year-on-year | 49% | 38% | |||
Symbicort | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 197 | $ 450 | |||
Actual %, year-on-year | 12% | 11% | |||
CER %, year-on-year | 25% | 21% | |||
Symbicort | Europe | |||||
Product sales | |||||
Product Sales | $ 143 | $ 286 | |||
Actual %, year-on-year | 4% | ||||
CER %, year-on-year | 5% | (1.00%) | |||
Symbicort | Established ROW | |||||
Product sales | |||||
Product Sales | $ 83 | $ 157 | |||
Actual %, year-on-year | (4.00%) | (4.00%) | |||
CER %, year-on-year | (1.00%) | (2.00%) | |||
Fasenra | |||||
Product sales | |||||
Product Sales | $ 423 | $ 781 | |||
Actual %, year-on-year | 4% | 5% | |||
CER %, year-on-year | 5% | 6% | |||
Fasenra | US | |||||
Product sales | |||||
Product Sales | $ 268 | $ 478 | |||
Actual %, year-on-year | 2% | ||||
Fasenra | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 19 | $ 41 | |||
Actual %, year-on-year | 33% | 45% | |||
CER %, year-on-year | 46% | 53% | |||
Fasenra | Europe | |||||
Product sales | |||||
Product Sales | $ 99 | $ 192 | |||
Actual %, year-on-year | 11% | 9% | |||
CER %, year-on-year | 11% | 8% | |||
Fasenra | Established ROW | |||||
Product sales | |||||
Product Sales | $ 37 | $ 70 | |||
Actual %, year-on-year | 3% | (2.00%) | |||
CER %, year-on-year | 11% | 6% | |||
Pulmicort | |||||
Product sales | |||||
Product Sales | $ 155 | $ 379 | |||
Actual %, year-on-year | 25% | 10% | |||
CER %, year-on-year | 30% | 14% | |||
Pulmicort | US | |||||
Product sales | |||||
Product Sales | $ 3 | $ 8 | |||
Actual %, year-on-year | (53.00%) | (53.00%) | |||
Pulmicort | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 126 | $ 317 | |||
Actual %, year-on-year | 40% | 16% | |||
CER %, year-on-year | 47% | 22% | |||
Pulmicort | Europe | |||||
Product sales | |||||
Product Sales | $ 17 | $ 37 | |||
Actual %, year-on-year | 6% | 1% | |||
CER %, year-on-year | 2% | (1.00%) | |||
Pulmicort | Established ROW | |||||
Product sales | |||||
Product Sales | $ 9 | $ 17 | |||
Actual %, year-on-year | (18.00%) | (13.00%) | |||
CER %, year-on-year | (13.00%) | (9.00%) | |||
Breztri | |||||
Product sales | |||||
Product Sales | $ 235 | $ 454 | |||
Actual %, year-on-year | 44% | 48% | |||
CER %, year-on-year | 47% | 51% | |||
Breztri | US | |||||
Product sales | |||||
Product Sales | $ 120 | $ 225 | |||
Actual %, year-on-year | 43% | 37% | |||
Breztri | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 61 | $ 131 | |||
Actual %, year-on-year | 42% | 61% | |||
CER %, year-on-year | 49% | 69% | |||
Breztri | Europe | |||||
Product sales | |||||
Product Sales | $ 35 | $ 65 | |||
Actual %, year-on-year | 68% | 80% | |||
CER %, year-on-year | 69% | 79% | |||
Breztri | Established ROW | |||||
Product sales | |||||
Product Sales | $ 19 | $ 33 | |||
Actual %, year-on-year | 26% | 33% | |||
CER %, year-on-year | 37% | 44% | |||
Tezspire | |||||
Product sales | |||||
Product Sales | $ 57 | $ 100 | |||
Tezspire | Emerging Markets | |||||
Product sales | |||||
Product Sales | 3 | 5 | |||
Tezspire | Europe | |||||
Product sales | |||||
Product Sales | 35 | 61 | |||
Tezspire | Established ROW | |||||
Product sales | |||||
Product Sales | 19 | 34 | |||
Saphnelo | |||||
Product sales | |||||
Product Sales | $ 112 | $ 203 | |||
Actual %, year-on-year | 65% | 77% | |||
CER %, year-on-year | 65% | 77% | |||
Saphnelo | US | |||||
Product sales | |||||
Product Sales | $ 101 | $ 184 | |||
Actual %, year-on-year | 59% | 71% | |||
Saphnelo | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 1 | $ 2 | |||
Actual %, year-on-year | 28% | ||||
Saphnelo | Europe | |||||
Product sales | |||||
Product Sales | $ 6 | 10 | |||
Saphnelo | Established ROW | |||||
Product sales | |||||
Product Sales | $ 4 | $ 7 | |||
Actual %, year-on-year | 90% | 86% | |||
CER %, year-on-year | 86% | 91% | |||
Airsupra | |||||
Product sales | |||||
Product Sales | $ 14 | $ 21 | |||
Airsupra | US | |||||
Product sales | |||||
Product Sales | 14 | 21 | |||
Respiratory, Others | |||||
Product sales | |||||
Product Sales | $ 79 | $ 172 | |||
Actual %, year-on-year | (24.00%) | (27.00%) | |||
CER %, year-on-year | (22.00%) | (26.00%) | |||
Respiratory, Others | US | |||||
Product sales | |||||
Product Sales | $ 25 | $ 53 | |||
Actual %, year-on-year | (52.00%) | (47.00%) | |||
Respiratory, Others | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 37 | $ 86 | |||
Actual %, year-on-year | 7% | (18.00%) | |||
CER %, year-on-year | 12% | (14.00%) | |||
Respiratory, Others | Europe | |||||
Product sales | |||||
Product Sales | $ 15 | $ 29 | |||
Actual %, year-on-year | 2% | 3% | |||
CER %, year-on-year | 3% | 2% | |||
Respiratory, Others | Established ROW | |||||
Product sales | |||||
Product Sales | $ 2 | $ 4 | |||
Actual %, year-on-year | (6.00%) | (12.00%) | |||
CER %, year-on-year | (4.00%) | (10.00%) | |||
BioPharmaceuticals: Total V&I | |||||
Product sales | |||||
Product Sales | $ 112 | $ 324 | |||
Actual %, year-on-year | 28% | (27.00%) | |||
CER %, year-on-year | 42% | (24.00%) | |||
BioPharmaceuticals: Total V&I | US | |||||
Product sales | |||||
Product Sales | $ 28 | $ 55 | |||
BioPharmaceuticals: Total V&I | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 41 | $ 131 | |||
Actual %, year-on-year | (10.00%) | (12.00%) | |||
CER %, year-on-year | 4% | (7.00%) | |||
BioPharmaceuticals: Total V&I | Europe | |||||
Product sales | |||||
Product Sales | $ 7 | $ 81 | |||
Actual %, year-on-year | (55.00%) | (28.00%) | |||
CER %, year-on-year | (53.00%) | (30.00%) | |||
BioPharmaceuticals: Total V&I | Established ROW | |||||
Product sales | |||||
Product Sales | $ 36 | $ 57 | |||
Actual %, year-on-year | 36% | (68.00%) | |||
CER %, year-on-year | 55% | (65.00%) | |||
Synagis | |||||
Product sales | |||||
Product Sales | $ 81 | $ 253 | |||
Actual %, year-on-year | (6.00%) | (11.00%) | |||
CER %, year-on-year | 8% | (6.00%) | |||
Synagis | US | |||||
Product sales | |||||
Product sales net of reversals | $ (1) | $ (1) | |||
Synagis | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 41 | $ 131 | |||
Actual %, year-on-year | (16.00%) | 4% | |||
CER %, year-on-year | (2.00%) | 10% | |||
Synagis | Europe | |||||
Product sales | |||||
Product Sales | $ 6 | $ 67 | |||
Actual %, year-on-year | (42.00%) | (27.00%) | |||
CER %, year-on-year | (42.00%) | (29.00%) | |||
Synagis | Established ROW | |||||
Product sales | |||||
Product Sales | $ 35 | $ 56 | |||
Actual %, year-on-year | 27% | (15.00%) | |||
CER %, year-on-year | 46% | (6.00%) | |||
Beyfortus | |||||
Product sales | |||||
Product Sales | $ 28 | $ 54 | |||
Beyfortus | US | |||||
Product sales | |||||
Product Sales | $ 27 | $ 53 | |||
Beyfortus | Europe | |||||
Product sales | |||||
Actual %, year-on-year | (81.00%) | ||||
CER %, year-on-year | (91.00%) | (61.00%) | |||
Beyfortus | Established ROW | |||||
Product sales | |||||
Product Sales | $ 1 | $ 1 | |||
FluMist | |||||
Product sales | |||||
Product Sales | 2 | 8 | |||
FluMist | US | |||||
Product sales | |||||
Product Sales | $ 2 | 3 | |||
FluMist | Europe | |||||
Product sales | |||||
Product Sales | $ 5 | ||||
Actual %, year-on-year | (26.00%) | ||||
CER %, year-on-year | (21.00%) | 97% | |||
Covid-19 mAbs | |||||
Product sales | |||||
Product Sales | $ 1 | $ 3 | |||
Actual %, year-on-year | (98.00%) | ||||
CER %, year-on-year | (98.00%) | ||||
Covid-19 mAbs | Europe | |||||
Product sales | |||||
Product Sales | $ 1 | $ 3 | |||
Actual %, year-on-year | (65.00%) | (58.00%) | |||
CER %, year-on-year | (64.00%) | (59.00%) | |||
Covid-19 mAbs | Established ROW | |||||
Product sales | |||||
Actual %, year-on-year | (99.00%) | ||||
CER %, year-on-year | (99.00%) | ||||
V&I, Others | |||||
Product sales | |||||
Product Sales | $ 6 | ||||
Actual %, year-on-year | (79.00%) | ||||
CER %, year-on-year | (80.00%) | ||||
V&I, Others | Europe | |||||
Product sales | |||||
Product Sales | $ 6 | ||||
Actual %, year-on-year | (41.00%) | ||||
CER %, year-on-year | (43.00%) | ||||
Total rare diseases | |||||
Product sales | |||||
Product Sales | $ 2,147 | $ 4,243 | |||
Actual %, year-on-year | 10% | 11% | |||
CER %, year-on-year | 14% | 15% | |||
Total rare diseases | US | |||||
Product sales | |||||
Product Sales | $ 1,311 | $ 2,517 | |||
Actual %, year-on-year | 10% | 10% | |||
Total rare diseases | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 203 | $ 454 | |||
Actual %, year-on-year | 35% | 40% | |||
CER %, year-on-year | 67% | 70% | |||
Total rare diseases | Europe | |||||
Product sales | |||||
Product Sales | $ 392 | $ 794 | |||
Actual %, year-on-year | 3% | 3% | |||
CER %, year-on-year | 3% | 2% | |||
Total rare diseases | Established ROW | |||||
Product sales | |||||
Product Sales | $ 241 | $ 478 | |||
Actual %, year-on-year | 7% | 9% | |||
CER %, year-on-year | 18% | 20% | |||
Ultomiris | |||||
Product sales | |||||
Product Sales | $ 946 | $ 1,804 | |||
Actual %, year-on-year | 33% | 32% | |||
CER %, year-on-year | 36% | 35% | |||
Ultomiris | US | |||||
Product sales | |||||
Product Sales | $ 550 | $ 1,032 | |||
Actual %, year-on-year | 27% | 27% | |||
Ultomiris | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 35 | $ 66 | |||
Ultomiris | Europe | |||||
Product sales | |||||
Product Sales | $ 209 | $ 411 | |||
Actual %, year-on-year | 38% | 32% | |||
CER %, year-on-year | 38% | 31% | |||
Ultomiris | Established ROW | |||||
Product sales | |||||
Product Sales | $ 152 | $ 295 | |||
Actual %, year-on-year | 38% | 42% | |||
CER %, year-on-year | 56% | 58% | |||
Soliris | |||||
Product sales | |||||
Product Sales | $ 700 | $ 1,439 | |||
Actual %, year-on-year | (14.00%) | (13.00%) | |||
CER %, year-on-year | (8.00%) | (8.00%) | |||
Soliris | US | |||||
Product sales | |||||
Product Sales | $ 398 | $ 808 | |||
Actual %, year-on-year | (11.00%) | (9.00%) | |||
Soliris | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 129 | $ 255 | |||
Actual %, year-on-year | 30% | 19% | |||
CER %, year-on-year | 74% | 54% | |||
Soliris | Europe | |||||
Product sales | |||||
Product Sales | $ 118 | $ 260 | |||
Actual %, year-on-year | (36.00%) | (29.00%) | |||
CER %, year-on-year | (36.00%) | (30.00%) | |||
Soliris | Established ROW | |||||
Product sales | |||||
Product Sales | $ 55 | $ 116 | |||
Actual %, year-on-year | (36.00%) | (33.00%) | |||
CER %, year-on-year | (33.00%) | (30.00%) | |||
Strensiq | |||||
Product sales | |||||
Product Sales | $ 340 | $ 653 | |||
Actual %, year-on-year | 13% | 16% | |||
CER %, year-on-year | 14% | 18% | |||
Strensiq | US | |||||
Product sales | |||||
Product Sales | $ 283 | $ 529 | |||
Actual %, year-on-year | 14% | 17% | |||
Strensiq | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 10 | $ 31 | |||
Actual %, year-on-year | 7% | 30% | |||
CER %, year-on-year | 15% | 47% | |||
Strensiq | Europe | |||||
Product sales | |||||
Product Sales | $ 24 | $ 48 | |||
Actual %, year-on-year | 13% | 14% | |||
CER %, year-on-year | 13% | 12% | |||
Strensiq | Established ROW | |||||
Product sales | |||||
Product Sales | $ 23 | $ 45 | |||
Actual %, year-on-year | 4% | 4% | |||
CER %, year-on-year | 17% | 15% | |||
Koselugo | |||||
Product sales | |||||
Product Sales | $ 114 | $ 247 | |||
Actual %, year-on-year | 43% | 55% | |||
CER %, year-on-year | 45% | 64% | |||
Koselugo | US | |||||
Product sales | |||||
Product Sales | $ 55 | $ 101 | |||
Actual %, year-on-year | 13% | 13% | |||
Koselugo | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 24 | $ 83 | |||
Actual %, year-on-year | 73% | ||||
CER %, year-on-year | 80% | ||||
Koselugo | Europe | |||||
Product sales | |||||
Product Sales | $ 26 | $ 45 | |||
Actual %, year-on-year | 95% | ||||
CER %, year-on-year | 92% | ||||
Koselugo | Established ROW | |||||
Product sales | |||||
Product Sales | $ 9 | $ 18 | |||
Actual %, year-on-year | 63% | ||||
CER %, year-on-year | 85% | ||||
Kanuma | |||||
Product sales | |||||
Product Sales | $ 47 | $ 100 | |||
Actual %, year-on-year | 3% | 17% | |||
CER %, year-on-year | 8% | 20% | |||
Kanuma | US | |||||
Product sales | |||||
Product Sales | $ 25 | $ 47 | |||
Actual %, year-on-year | 21% | 18% | |||
Kanuma | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 5 | $ 19 | |||
Actual %, year-on-year | (54.00%) | 7% | |||
CER %, year-on-year | (49.00%) | 20% | |||
Kanuma | Europe | |||||
Product sales | |||||
Product Sales | $ 15 | $ 30 | |||
Actual %, year-on-year | 28% | 24% | |||
CER %, year-on-year | 33% | 25% | |||
Kanuma | Established ROW | |||||
Product sales | |||||
Product Sales | $ 2 | $ 4 | |||
Actual %, year-on-year | 11% | 11% | |||
CER %, year-on-year | 41% | 20% | |||
Total Other medicines | |||||
Product sales | |||||
Product Sales | $ 267 | $ 560 | |||
Actual %, year-on-year | (11.00%) | (9.00%) | |||
CER %, year-on-year | (5.00%) | (2.00%) | |||
Total Other medicines | US | |||||
Product sales | |||||
Product Sales | $ 28 | $ 52 | |||
Actual %, year-on-year | (13.00%) | (24.00%) | |||
Total Other medicines | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 179 | $ 385 | |||
Actual %, year-on-year | (3.00%) | (1.00%) | |||
CER %, year-on-year | 5% | 8% | |||
Total Other medicines | Europe | |||||
Product sales | |||||
Product Sales | $ 24 | $ 53 | |||
Actual %, year-on-year | (7.00%) | 10% | |||
CER %, year-on-year | (7.00%) | 10% | |||
Total Other medicines | Established ROW | |||||
Product sales | |||||
Product Sales | $ 36 | $ 70 | |||
Actual %, year-on-year | (38.00%) | (35.00%) | |||
CER %, year-on-year | (32.00%) | (29.00%) | |||
Nexium | |||||
Product sales | |||||
Product Sales | $ 219 | $ 459 | |||
Actual %, year-on-year | (12.00%) | (7.00%) | |||
CER %, year-on-year | (5.00%) | 1% | |||
Nexium | US | |||||
Product sales | |||||
Product Sales | $ 25 | $ 47 | |||
Actual %, year-on-year | (17.00%) | (22.00%) | |||
Nexium | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 146 | $ 318 | |||
Actual %, year-on-year | (2.00%) | 4% | |||
CER %, year-on-year | 7% | 15% | |||
Nexium | Europe | |||||
Product sales | |||||
Product Sales | $ 13 | $ 26 | |||
Actual %, year-on-year | (5.00%) | 3% | |||
CER %, year-on-year | (5.00%) | 2% | |||
Nexium | Established ROW | |||||
Product sales | |||||
Product Sales | $ 35 | $ 68 | |||
Actual %, year-on-year | (37.00%) | (34.00%) | |||
CER %, year-on-year | (32.00%) | (28.00%) | |||
Other, Others | |||||
Product sales | |||||
Product Sales | $ 48 | $ 101 | |||
Actual %, year-on-year | (9.00%) | (17.00%) | |||
CER %, year-on-year | (6.00%) | (14.00%) | |||
Other, Others | US | |||||
Product sales | |||||
Product Sales | $ 3 | $ 5 | |||
Actual %, year-on-year | 39% | (40.00%) | |||
Other, Others | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 33 | $ 67 | |||
Actual %, year-on-year | (8.00%) | (22.00%) | |||
CER %, year-on-year | (4.00%) | (18.00%) | |||
Other, Others | Europe | |||||
Product sales | |||||
Product Sales | $ 11 | $ 27 | |||
Actual %, year-on-year | (9.00%) | 18% | |||
CER %, year-on-year | (9.00%) | 19% | |||
Other, Others | Established ROW | |||||
Product sales | |||||
Product Sales | $ 1 | $ 2 | |||
Actual %, year-on-year | (54.00%) | (53.00%) | |||
CER %, year-on-year | (49.00%) | (49.00%) | |||
[1] The Q2 2024 and Q2 2023 information in respect of the three months ended 30 June 2024 and 30 June 2023 respectively included in the Interim financial statements have not been reviewed by PricewaterhouseCoopers LLP. |
Q2 2024 Product Sales year-on_2
Q2 2024 Product Sales year-on-year analysis (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | ||
Product sales | |||||
Product Sales | $ 12,452 | [1] | $ 10,882 | $ 24,629 | $ 21,448 |
Actual %, year-on-year | 14% | 15% | |||
CER %, year-on-year | 18% | 18% | |||
US | |||||
Product sales | |||||
Product Sales | $ 5,234 | $ 10,061 | |||
Actual %, year-on-year | 16% | 17% | |||
Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 3,349 | $ 7,051 | |||
Actual %, year-on-year | 15% | 16% | |||
CER %, year-on-year | 25% | 26% | |||
Europe | |||||
Product sales | |||||
Product Sales | $ 2,631 | $ 5,134 | |||
Actual %, year-on-year | 23% | 21% | |||
CER %, year-on-year | 23% | 19% | |||
Established ROW | |||||
Product sales | |||||
Product Sales | $ 1,238 | $ 2,383 | |||
Actual %, year-on-year | (5.00%) | (6.00%) | |||
CER %, year-on-year | 5% | 3% | |||
Total Oncology | |||||
Product sales | |||||
Product Sales | $ 4,976 | $ 9,737 | |||
Actual %, year-on-year | 14% | 17% | |||
CER %, year-on-year | 18% | 21% | |||
Total Oncology | US | |||||
Product sales | |||||
Product Sales | $ 2,302 | $ 4,387 | |||
Actual %, year-on-year | 17% | 20% | |||
Total Oncology | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 1,098 | $ 2,300 | |||
Actual %, year-on-year | 11% | 18% | |||
CER %, year-on-year | 22% | 28% | |||
Total Oncology | Europe | |||||
Product sales | |||||
Product Sales | $ 1,015 | $ 1,967 | |||
Actual %, year-on-year | 24% | 25% | |||
CER %, year-on-year | 24% | 23% | |||
Total Oncology | Established ROW | |||||
Product sales | |||||
Product Sales | $ 561 | $ 1,083 | |||
Actual %, year-on-year | (9.00%) | (2.00%) | |||
CER %, year-on-year | 2% | 8% | |||
Tagrisso | |||||
Product sales | |||||
Product Sales | $ 1,608 | $ 3,203 | |||
Actual %, year-on-year | 8% | 10% | |||
CER %, year-on-year | 12% | 13% | |||
Tagrisso | US | |||||
Product sales | |||||
Product Sales | $ 658 | $ 1,282 | |||
Actual %, year-on-year | 13% | 16% | |||
Tagrisso | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 432 | $ 919 | |||
Actual %, year-on-year | 6% | 8% | |||
CER %, year-on-year | 15% | 16% | |||
Tagrisso | Europe | |||||
Product sales | |||||
Product Sales | $ 327 | $ 628 | |||
Actual %, year-on-year | 15% | 16% | |||
CER %, year-on-year | 15% | 15% | |||
Tagrisso | Established ROW | |||||
Product sales | |||||
Product Sales | $ 191 | $ 374 | |||
Actual %, year-on-year | (12.00%) | (11.00%) | |||
CER %, year-on-year | (1.00%) | (2.00%) | |||
Imfinzi | |||||
Product sales | |||||
Product Sales | $ 1,147 | $ 2,259 | |||
Actual %, year-on-year | 13% | 20% | |||
CER %, year-on-year | 18% | 25% | |||
Imfinzi | US | |||||
Product sales | |||||
Product Sales | $ 620 | $ 1,202 | |||
Actual %, year-on-year | 15% | 17% | |||
Imfinzi | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 117 | $ 245 | |||
Actual %, year-on-year | 16% | 35% | |||
CER %, year-on-year | 39% | 58% | |||
Imfinzi | Europe | |||||
Product sales | |||||
Product Sales | $ 227 | $ 459 | |||
Actual %, year-on-year | 33% | 38% | |||
CER %, year-on-year | 33% | 36% | |||
Imfinzi | Established ROW | |||||
Product sales | |||||
Product Sales | $ 183 | $ 353 | |||
Actual %, year-on-year | (9.00%) | 7% | |||
CER %, year-on-year | 3% | 19% | |||
Lynparza | |||||
Product sales | |||||
Product Sales | $ 744 | $ 1,450 | |||
Actual %, year-on-year | 4% | 6% | |||
CER %, year-on-year | 7% | 9% | |||
Lynparza | US | |||||
Product sales | |||||
Product Sales | $ 319 | $ 607 | |||
Actual %, year-on-year | 3% | 5% | |||
Lynparza | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 153 | $ 320 | |||
Actual %, year-on-year | 8% | 15% | |||
CER %, year-on-year | 18% | 26% | |||
Lynparza | Europe | |||||
Product sales | |||||
Product Sales | $ 206 | $ 398 | |||
Actual %, year-on-year | 10% | 9% | |||
CER %, year-on-year | 11% | 8% | |||
Lynparza | Established ROW | |||||
Product sales | |||||
Product Sales | $ 66 | $ 125 | |||
Actual %, year-on-year | (15.00%) | (14.00%) | |||
CER %, year-on-year | (6.00%) | (6.00%) | |||
Calquence | |||||
Product sales | |||||
Product Sales | $ 790 | $ 1,508 | |||
Actual %, year-on-year | 21% | 27% | |||
CER %, year-on-year | 22% | 28% | |||
Calquence | US | |||||
Product sales | |||||
Product Sales | $ 554 | $ 1,048 | |||
Actual %, year-on-year | 14% | 21% | |||
Calquence | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 36 | $ 75 | |||
Actual %, year-on-year | 51% | 82% | |||
CER %, year-on-year | 72% | ||||
Calquence | Europe | |||||
Product sales | |||||
Product Sales | $ 167 | $ 320 | |||
Actual %, year-on-year | 42% | 42% | |||
CER %, year-on-year | 43% | 41% | |||
Calquence | Established ROW | |||||
Product sales | |||||
Product Sales | $ 33 | $ 65 | |||
Actual %, year-on-year | 20% | 30% | |||
CER %, year-on-year | 23% | 34% | |||
Enhertu | |||||
Product sales | |||||
Product Sales | $ 127 | $ 249 | |||
Actual %, year-on-year | 89% | ||||
CER %, year-on-year | 99% | ||||
Enhertu | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 77 | 161 | |||
Actual %, year-on-year | 60% | ||||
CER %, year-on-year | 72% | ||||
Enhertu | Europe | |||||
Product sales | |||||
Product Sales | $ 31 | 57 | |||
Enhertu | Established ROW | |||||
Product sales | |||||
Product Sales | 19 | 31 | |||
Orpathys | |||||
Product sales | |||||
Product Sales | $ 12 | $ 25 | |||
Actual %, year-on-year | (7.00%) | 14% | |||
CER %, year-on-year | (3.00%) | 19% | |||
Orpathys | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 12 | $ 25 | |||
Actual %, year-on-year | (7.00%) | 14% | |||
CER %, year-on-year | (3.00%) | 19% | |||
Truqap | |||||
Product sales | |||||
Product Sales | $ 92 | $ 142 | |||
Truqap | US | |||||
Product sales | |||||
Product Sales | 91 | 141 | |||
Truqap | Established ROW | |||||
Product sales | |||||
Product Sales | 1 | 1 | |||
Zoladex | |||||
Product sales | |||||
Product Sales | $ 273 | $ 549 | |||
Actual %, year-on-year | 17% | 19% | |||
CER %, year-on-year | 25% | 27% | |||
Zoladex | US | |||||
Product sales | |||||
Product Sales | $ 5 | $ 8 | |||
Actual %, year-on-year | 29% | 20% | |||
Zoladex | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 201 | $ 415 | |||
Actual %, year-on-year | 17% | 22% | |||
CER %, year-on-year | 28% | 31% | |||
Zoladex | Europe | |||||
Product sales | |||||
Product Sales | $ 42 | $ 77 | |||
Actual %, year-on-year | 23% | 16% | |||
CER %, year-on-year | 21% | 14% | |||
Zoladex | Established ROW | |||||
Product sales | |||||
Product Sales | $ 25 | $ 49 | |||
Actual %, year-on-year | 6% | 2% | |||
CER %, year-on-year | 17% | 12% | |||
Oncology, Others | |||||
Product sales | |||||
Product Sales | $ 109 | $ 216 | |||
Actual %, year-on-year | (17.00%) | (21.00%) | |||
CER %, year-on-year | (11.00%) | (15.00%) | |||
Oncology, Others | US | |||||
Product sales | |||||
Product Sales | $ 6 | $ 11 | |||
Actual %, year-on-year | 24% | 6% | |||
Oncology, Others | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 66 | $ 133 | |||
Actual %, year-on-year | (16.00%) | (21.00%) | |||
CER %, year-on-year | (10.00%) | (15.00%) | |||
Oncology, Others | Europe | |||||
Product sales | |||||
Product Sales | $ 7 | $ 12 | |||
Actual %, year-on-year | (11.00%) | (36.00%) | |||
CER %, year-on-year | (10.00%) | (36.00%) | |||
Oncology, Others | Established ROW | |||||
Product sales | |||||
Product Sales | $ 30 | $ 60 | |||
Actual %, year-on-year | (26.00%) | (21.00%) | |||
CER %, year-on-year | (16.00%) | (12.00%) | |||
BioPharmaceuticals: total CVRM | |||||
Product sales | |||||
Product Sales | $ 3,153 | $ 6,164 | |||
Actual %, year-on-year | 18% | 18% | |||
CER %, year-on-year | 22% | 22% | |||
BioPharmaceuticals: total CVRM | US | |||||
Product sales | |||||
Product Sales | $ 735 | $ 1,483 | |||
Actual %, year-on-year | 11% | 16% | |||
BioPharmaceuticals: total CVRM | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 1,384 | $ 2,749 | |||
Actual %, year-on-year | 17% | 17% | |||
CER %, year-on-year | 24% | 24% | |||
BioPharmaceuticals: total CVRM | Europe | |||||
Product sales | |||||
Product Sales | $ 843 | $ 1,559 | |||
Actual %, year-on-year | 38% | 33% | |||
CER %, year-on-year | 38% | 32% | |||
BioPharmaceuticals: total CVRM | Established ROW | |||||
Product sales | |||||
Product Sales | $ 191 | $ 373 | |||
Actual %, year-on-year | (14.00%) | (8.00%) | |||
CER %, year-on-year | (3.00%) | 2% | |||
Farxiga | |||||
Product sales | |||||
Product Sales | $ 1,940 | $ 3,785 | |||
Actual %, year-on-year | 29% | 35% | |||
CER %, year-on-year | 32% | 38% | |||
Farxiga | US | |||||
Product sales | |||||
Product Sales | $ 394 | $ 867 | |||
Actual %, year-on-year | 16% | 37% | |||
Farxiga | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 763 | $ 1,474 | |||
Actual %, year-on-year | 32% | 37% | |||
CER %, year-on-year | 39% | 44% | |||
Farxiga | Europe | |||||
Product sales | |||||
Product Sales | $ 680 | $ 1,233 | |||
Actual %, year-on-year | 49% | 45% | |||
CER %, year-on-year | 49% | 44% | |||
Farxiga | Established ROW | |||||
Product sales | |||||
Product Sales | $ 103 | $ 211 | |||
Actual %, year-on-year | (23.00%) | (15.00%) | |||
CER %, year-on-year | (14.00%) | (5.00%) | |||
Brilinta | |||||
Product sales | |||||
Product Sales | $ 342 | $ 665 | |||
Actual %, year-on-year | 3% | ||||
CER %, year-on-year | 5% | 2% | |||
Brilinta | US | |||||
Product sales | |||||
Product Sales | $ 191 | $ 354 | |||
Actual %, year-on-year | 7% | (1.00%) | |||
Brilinta | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 78 | $ 166 | |||
Actual %, year-on-year | (1.00%) | 4% | |||
CER %, year-on-year | 6% | 14% | |||
Brilinta | Europe | |||||
Product sales | |||||
Product Sales | $ 69 | $ 136 | |||
Actual %, year-on-year | 1% | ||||
CER %, year-on-year | 1% | (1.00%) | |||
Brilinta | Established ROW | |||||
Product sales | |||||
Product Sales | $ 4 | $ 9 | |||
Actual %, year-on-year | (38.00%) | (26.00%) | |||
CER %, year-on-year | (23.00%) | (19.00%) | |||
Lokelma | |||||
Product sales | |||||
Product Sales | $ 136 | $ 249 | |||
Actual %, year-on-year | 36% | 26% | |||
CER %, year-on-year | 41% | 30% | |||
Lokelma | US | |||||
Product sales | |||||
Product Sales | $ 64 | $ 115 | |||
Actual %, year-on-year | 29% | 10% | |||
Lokelma | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 21 | $ 42 | |||
Actual %, year-on-year | 68% | 75% | |||
CER %, year-on-year | 78% | 83% | |||
Lokelma | Europe | |||||
Product sales | |||||
Product Sales | $ 23 | $ 41 | |||
Actual %, year-on-year | 63% | 62% | |||
CER %, year-on-year | 64% | 61% | |||
Lokelma | Established ROW | |||||
Product sales | |||||
Product Sales | $ 28 | $ 51 | |||
Actual %, year-on-year | 16% | 16% | |||
CER %, year-on-year | 33% | 31% | |||
roxadustat | |||||
Product sales | |||||
Product Sales | $ 88 | $ 163 | |||
Actual %, year-on-year | 20% | 22% | |||
CER %, year-on-year | 26% | 27% | |||
roxadustat | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 88 | $ 163 | |||
Actual %, year-on-year | 20% | 22% | |||
CER %, year-on-year | 26% | 27% | |||
Crestor. | |||||
Product sales | |||||
Product Sales | $ 292 | $ 589 | |||
Actual %, year-on-year | 4% | 1% | |||
CER %, year-on-year | 11% | 6% | |||
Crestor. | US | |||||
Product sales | |||||
Product Sales | $ 12 | $ 22 | |||
Actual %, year-on-year | (2.00%) | (18.00%) | |||
Crestor. | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 234 | $ 475 | |||
Actual %, year-on-year | 8% | 4% | |||
CER %, year-on-year | 14% | 9% | |||
Crestor. | Europe | |||||
Product sales | |||||
Product Sales | $ 10 | $ 22 | |||
Actual %, year-on-year | (34.00%) | (30.00%) | |||
CER %, year-on-year | (32.00%) | (29.00%) | |||
Crestor. | Established ROW | |||||
Product sales | |||||
Product Sales | $ 36 | $ 70 | |||
Actual %, year-on-year | 3% | 3% | |||
CER %, year-on-year | 15% | 13% | |||
Seloken/Toprol-XL | |||||
Product sales | |||||
Product Sales | $ 150 | $ 315 | |||
Actual %, year-on-year | (8.00%) | (8.00%) | |||
CER %, year-on-year | (1.00%) | ||||
Seloken/Toprol-XL | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 146 | $ 307 | |||
Actual %, year-on-year | (8.00%) | (8.00%) | |||
CER %, year-on-year | (1.00%) | ||||
Seloken/Toprol-XL | Europe | |||||
Product sales | |||||
Product Sales | $ 3 | $ 6 | |||
Actual %, year-on-year | 46% | 4% | |||
CER %, year-on-year | 53% | 7% | |||
Seloken/Toprol-XL | Established ROW | |||||
Product sales | |||||
Product Sales | $ 1 | $ 2 | |||
Actual %, year-on-year | (40.00%) | (39.00%) | |||
CER %, year-on-year | (38.00%) | (37.00%) | |||
CVRM, Others | |||||
Product sales | |||||
Product Sales | $ 130 | $ 272 | |||
Actual %, year-on-year | (26.00%) | (30.00%) | |||
CER %, year-on-year | (24.00%) | (28.00%) | |||
CVRM, Others | US | |||||
Product sales | |||||
Product Sales | $ 36 | $ 62 | |||
Actual %, year-on-year | (45.00%) | (50.00%) | |||
CVRM, Others | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 53 | $ 120 | |||
Actual %, year-on-year | (19.00%) | (27.00%) | |||
CER %, year-on-year | (14.00%) | (22.00%) | |||
CVRM, Others | Europe | |||||
Product sales | |||||
Product Sales | $ 36 | $ 81 | |||
Actual %, year-on-year | (9.00%) | (10.00%) | |||
CER %, year-on-year | (8.00%) | (10.00%) | |||
CVRM, Others | Established ROW | |||||
Product sales | |||||
Product Sales | $ 5 | $ 9 | |||
Actual %, year-on-year | (14.00%) | (7.00%) | |||
CER %, year-on-year | (12.00%) | (5.00%) | |||
BioPharmaceuticals: total Respiratory & Immunology | |||||
Product sales | |||||
Product Sales | $ 1,797 | $ 3,601 | |||
Actual %, year-on-year | 21% | 17% | |||
CER %, year-on-year | 24% | 20% | |||
BioPharmaceuticals: total Respiratory & Immunology | US | |||||
Product sales | |||||
Product Sales | $ 830 | $ 1,567 | |||
Actual %, year-on-year | 23% | 21% | |||
BioPharmaceuticals: total Respiratory & Immunology | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 444 | $ 1,032 | |||
Actual %, year-on-year | 23% | 16% | |||
CER %, year-on-year | 34% | 23% | |||
BioPharmaceuticals: total Respiratory & Immunology | Europe | |||||
Product sales | |||||
Product Sales | $ 350 | $ 680 | |||
Actual %, year-on-year | 21% | 17% | |||
CER %, year-on-year | 21% | 16% | |||
BioPharmaceuticals: total Respiratory & Immunology | Established ROW | |||||
Product sales | |||||
Product Sales | $ 173 | $ 322 | |||
Actual %, year-on-year | 8% | 7% | |||
CER %, year-on-year | 14% | 12% | |||
Symbicort | |||||
Product sales | |||||
Product Sales | $ 722 | $ 1,491 | |||
Actual %, year-on-year | 20% | 16% | |||
CER %, year-on-year | 25% | 19% | |||
Symbicort | US | |||||
Product sales | |||||
Product Sales | $ 299 | $ 598 | |||
Actual %, year-on-year | 49% | 38% | |||
Symbicort | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 197 | $ 450 | |||
Actual %, year-on-year | 12% | 11% | |||
CER %, year-on-year | 25% | 21% | |||
Symbicort | Europe | |||||
Product sales | |||||
Product Sales | $ 143 | $ 286 | |||
Actual %, year-on-year | 4% | ||||
CER %, year-on-year | 5% | (1.00%) | |||
Symbicort | Established ROW | |||||
Product sales | |||||
Product Sales | $ 83 | $ 157 | |||
Actual %, year-on-year | (4.00%) | (4.00%) | |||
CER %, year-on-year | (1.00%) | (2.00%) | |||
Fasenra | |||||
Product sales | |||||
Product Sales | $ 423 | $ 781 | |||
Actual %, year-on-year | 4% | 5% | |||
CER %, year-on-year | 5% | 6% | |||
Fasenra | US | |||||
Product sales | |||||
Product Sales | $ 268 | $ 478 | |||
Actual %, year-on-year | 2% | ||||
Fasenra | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 19 | $ 41 | |||
Actual %, year-on-year | 33% | 45% | |||
CER %, year-on-year | 46% | 53% | |||
Fasenra | Europe | |||||
Product sales | |||||
Product Sales | $ 99 | $ 192 | |||
Actual %, year-on-year | 11% | 9% | |||
CER %, year-on-year | 11% | 8% | |||
Fasenra | Established ROW | |||||
Product sales | |||||
Product Sales | $ 37 | $ 70 | |||
Actual %, year-on-year | 3% | (2.00%) | |||
CER %, year-on-year | 11% | 6% | |||
Breztri | |||||
Product sales | |||||
Product Sales | $ 235 | $ 454 | |||
Actual %, year-on-year | 44% | 48% | |||
CER %, year-on-year | 47% | 51% | |||
Breztri | US | |||||
Product sales | |||||
Product Sales | $ 120 | $ 225 | |||
Actual %, year-on-year | 43% | 37% | |||
Breztri | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 61 | $ 131 | |||
Actual %, year-on-year | 42% | 61% | |||
CER %, year-on-year | 49% | 69% | |||
Breztri | Europe | |||||
Product sales | |||||
Product Sales | $ 35 | $ 65 | |||
Actual %, year-on-year | 68% | 80% | |||
CER %, year-on-year | 69% | 79% | |||
Breztri | Established ROW | |||||
Product sales | |||||
Product Sales | $ 19 | $ 33 | |||
Actual %, year-on-year | 26% | 33% | |||
CER %, year-on-year | 37% | 44% | |||
Saphnelo | |||||
Product sales | |||||
Product Sales | $ 112 | $ 203 | |||
Actual %, year-on-year | 65% | 77% | |||
CER %, year-on-year | 65% | 77% | |||
Saphnelo | US | |||||
Product sales | |||||
Product Sales | $ 101 | $ 184 | |||
Actual %, year-on-year | 59% | 71% | |||
Saphnelo | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 1 | $ 2 | |||
Actual %, year-on-year | 28% | ||||
Saphnelo | Europe | |||||
Product sales | |||||
Product Sales | $ 6 | 10 | |||
Saphnelo | Established ROW | |||||
Product sales | |||||
Product Sales | $ 4 | $ 7 | |||
Actual %, year-on-year | 90% | 86% | |||
CER %, year-on-year | 86% | 91% | |||
Tezspire | |||||
Product sales | |||||
Product Sales | $ 57 | $ 100 | |||
Tezspire | Emerging Markets | |||||
Product sales | |||||
Product Sales | 3 | 5 | |||
Tezspire | Europe | |||||
Product sales | |||||
Product Sales | 35 | 61 | |||
Tezspire | Established ROW | |||||
Product sales | |||||
Product Sales | 19 | 34 | |||
Pulmicort | |||||
Product sales | |||||
Product Sales | $ 155 | $ 379 | |||
Actual %, year-on-year | 25% | 10% | |||
CER %, year-on-year | 30% | 14% | |||
Pulmicort | US | |||||
Product sales | |||||
Product Sales | $ 3 | $ 8 | |||
Actual %, year-on-year | (53.00%) | (53.00%) | |||
Pulmicort | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 126 | $ 317 | |||
Actual %, year-on-year | 40% | 16% | |||
CER %, year-on-year | 47% | 22% | |||
Pulmicort | Europe | |||||
Product sales | |||||
Product Sales | $ 17 | $ 37 | |||
Actual %, year-on-year | 6% | 1% | |||
CER %, year-on-year | 2% | (1.00%) | |||
Pulmicort | Established ROW | |||||
Product sales | |||||
Product Sales | $ 9 | $ 17 | |||
Actual %, year-on-year | (18.00%) | (13.00%) | |||
CER %, year-on-year | (13.00%) | (9.00%) | |||
Respiratory, Others | |||||
Product sales | |||||
Product Sales | $ 79 | $ 172 | |||
Actual %, year-on-year | (24.00%) | (27.00%) | |||
CER %, year-on-year | (22.00%) | (26.00%) | |||
Respiratory, Others | US | |||||
Product sales | |||||
Product Sales | $ 25 | $ 53 | |||
Actual %, year-on-year | (52.00%) | (47.00%) | |||
Respiratory, Others | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 37 | $ 86 | |||
Actual %, year-on-year | 7% | (18.00%) | |||
CER %, year-on-year | 12% | (14.00%) | |||
Respiratory, Others | Europe | |||||
Product sales | |||||
Product Sales | $ 15 | $ 29 | |||
Actual %, year-on-year | 2% | 3% | |||
CER %, year-on-year | 3% | 2% | |||
Respiratory, Others | Established ROW | |||||
Product sales | |||||
Product Sales | $ 2 | $ 4 | |||
Actual %, year-on-year | (6.00%) | (12.00%) | |||
CER %, year-on-year | (4.00%) | (10.00%) | |||
BioPharmaceuticals: Total V&I | |||||
Product sales | |||||
Product Sales | $ 112 | $ 324 | |||
Actual %, year-on-year | 28% | (27.00%) | |||
CER %, year-on-year | 42% | (24.00%) | |||
BioPharmaceuticals: Total V&I | US | |||||
Product sales | |||||
Product Sales | $ 28 | $ 55 | |||
BioPharmaceuticals: Total V&I | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 41 | $ 131 | |||
Actual %, year-on-year | (10.00%) | (12.00%) | |||
CER %, year-on-year | 4% | (7.00%) | |||
BioPharmaceuticals: Total V&I | Europe | |||||
Product sales | |||||
Product Sales | $ 7 | $ 81 | |||
Actual %, year-on-year | (55.00%) | (28.00%) | |||
CER %, year-on-year | (53.00%) | (30.00%) | |||
BioPharmaceuticals: Total V&I | Established ROW | |||||
Product sales | |||||
Product Sales | $ 36 | $ 57 | |||
Actual %, year-on-year | 36% | (68.00%) | |||
CER %, year-on-year | 55% | (65.00%) | |||
Covid-19 mAbs | |||||
Product sales | |||||
Product Sales | $ 1 | $ 3 | |||
Actual %, year-on-year | (98.00%) | ||||
CER %, year-on-year | (98.00%) | ||||
Covid-19 mAbs | Europe | |||||
Product sales | |||||
Product Sales | $ 1 | $ 3 | |||
Actual %, year-on-year | (65.00%) | (58.00%) | |||
CER %, year-on-year | (64.00%) | (59.00%) | |||
Covid-19 mAbs | Established ROW | |||||
Product sales | |||||
Actual %, year-on-year | (99.00%) | ||||
CER %, year-on-year | (99.00%) | ||||
Beyfortus | |||||
Product sales | |||||
Product Sales | $ 28 | $ 54 | |||
Beyfortus | US | |||||
Product sales | |||||
Product Sales | $ 27 | $ 53 | |||
Beyfortus | Europe | |||||
Product sales | |||||
Actual %, year-on-year | (81.00%) | ||||
CER %, year-on-year | (91.00%) | (61.00%) | |||
Beyfortus | Established ROW | |||||
Product sales | |||||
Product Sales | $ 1 | $ 1 | |||
Synagis | |||||
Product sales | |||||
Product Sales | $ 81 | $ 253 | |||
Actual %, year-on-year | (6.00%) | (11.00%) | |||
CER %, year-on-year | 8% | (6.00%) | |||
Synagis | US | |||||
Product sales | |||||
Product sales net of reversals | $ (1) | $ (1) | |||
Synagis | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 41 | $ 131 | |||
Actual %, year-on-year | (16.00%) | 4% | |||
CER %, year-on-year | (2.00%) | 10% | |||
Synagis | Europe | |||||
Product sales | |||||
Product Sales | $ 6 | $ 67 | |||
Actual %, year-on-year | (42.00%) | (27.00%) | |||
CER %, year-on-year | (42.00%) | (29.00%) | |||
Synagis | Established ROW | |||||
Product sales | |||||
Product Sales | $ 35 | $ 56 | |||
Actual %, year-on-year | 27% | (15.00%) | |||
CER %, year-on-year | 46% | (6.00%) | |||
FluMist | |||||
Product sales | |||||
Product Sales | $ 2 | $ 8 | |||
FluMist | US | |||||
Product sales | |||||
Product Sales | $ 2 | 3 | |||
FluMist | Europe | |||||
Product sales | |||||
Product Sales | $ 5 | ||||
Actual %, year-on-year | (26.00%) | ||||
CER %, year-on-year | (21.00%) | 97% | |||
Total rare diseases | |||||
Product sales | |||||
Product Sales | $ 2,147 | $ 4,243 | |||
Actual %, year-on-year | 10% | 11% | |||
CER %, year-on-year | 14% | 15% | |||
Total rare diseases | US | |||||
Product sales | |||||
Product Sales | $ 1,311 | $ 2,517 | |||
Actual %, year-on-year | 10% | 10% | |||
Total rare diseases | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 203 | $ 454 | |||
Actual %, year-on-year | 35% | 40% | |||
CER %, year-on-year | 67% | 70% | |||
Total rare diseases | Europe | |||||
Product sales | |||||
Product Sales | $ 392 | $ 794 | |||
Actual %, year-on-year | 3% | 3% | |||
CER %, year-on-year | 3% | 2% | |||
Total rare diseases | Established ROW | |||||
Product sales | |||||
Product Sales | $ 241 | $ 478 | |||
Actual %, year-on-year | 7% | 9% | |||
CER %, year-on-year | 18% | 20% | |||
Soliris | |||||
Product sales | |||||
Product Sales | $ 700 | $ 1,439 | |||
Actual %, year-on-year | (14.00%) | (13.00%) | |||
CER %, year-on-year | (8.00%) | (8.00%) | |||
Soliris | US | |||||
Product sales | |||||
Product Sales | $ 398 | $ 808 | |||
Actual %, year-on-year | (11.00%) | (9.00%) | |||
Soliris | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 129 | $ 255 | |||
Actual %, year-on-year | 30% | 19% | |||
CER %, year-on-year | 74% | 54% | |||
Soliris | Europe | |||||
Product sales | |||||
Product Sales | $ 118 | $ 260 | |||
Actual %, year-on-year | (36.00%) | (29.00%) | |||
CER %, year-on-year | (36.00%) | (30.00%) | |||
Soliris | Established ROW | |||||
Product sales | |||||
Product Sales | $ 55 | $ 116 | |||
Actual %, year-on-year | (36.00%) | (33.00%) | |||
CER %, year-on-year | (33.00%) | (30.00%) | |||
Ultomiris | |||||
Product sales | |||||
Product Sales | $ 946 | $ 1,804 | |||
Actual %, year-on-year | 33% | 32% | |||
CER %, year-on-year | 36% | 35% | |||
Ultomiris | US | |||||
Product sales | |||||
Product Sales | $ 550 | $ 1,032 | |||
Actual %, year-on-year | 27% | 27% | |||
Ultomiris | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 35 | $ 66 | |||
Ultomiris | Europe | |||||
Product sales | |||||
Product Sales | $ 209 | $ 411 | |||
Actual %, year-on-year | 38% | 32% | |||
CER %, year-on-year | 38% | 31% | |||
Ultomiris | Established ROW | |||||
Product sales | |||||
Product Sales | $ 152 | $ 295 | |||
Actual %, year-on-year | 38% | 42% | |||
CER %, year-on-year | 56% | 58% | |||
Strensiq | |||||
Product sales | |||||
Product Sales | $ 340 | $ 653 | |||
Actual %, year-on-year | 13% | 16% | |||
CER %, year-on-year | 14% | 18% | |||
Strensiq | US | |||||
Product sales | |||||
Product Sales | $ 283 | $ 529 | |||
Actual %, year-on-year | 14% | 17% | |||
Strensiq | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 10 | $ 31 | |||
Actual %, year-on-year | 7% | 30% | |||
CER %, year-on-year | 15% | 47% | |||
Strensiq | Europe | |||||
Product sales | |||||
Product Sales | $ 24 | $ 48 | |||
Actual %, year-on-year | 13% | 14% | |||
CER %, year-on-year | 13% | 12% | |||
Strensiq | Established ROW | |||||
Product sales | |||||
Product Sales | $ 23 | $ 45 | |||
Actual %, year-on-year | 4% | 4% | |||
CER %, year-on-year | 17% | 15% | |||
Koselugo | |||||
Product sales | |||||
Product Sales | $ 114 | $ 247 | |||
Actual %, year-on-year | 43% | 55% | |||
CER %, year-on-year | 45% | 64% | |||
Koselugo | US | |||||
Product sales | |||||
Product Sales | $ 55 | $ 101 | |||
Actual %, year-on-year | 13% | 13% | |||
Koselugo | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 24 | $ 83 | |||
Actual %, year-on-year | 73% | ||||
CER %, year-on-year | 80% | ||||
Koselugo | Europe | |||||
Product sales | |||||
Product Sales | $ 26 | $ 45 | |||
Actual %, year-on-year | 95% | ||||
CER %, year-on-year | 92% | ||||
Koselugo | Established ROW | |||||
Product sales | |||||
Product Sales | $ 9 | $ 18 | |||
Actual %, year-on-year | 63% | ||||
CER %, year-on-year | 85% | ||||
Kanuma | |||||
Product sales | |||||
Product Sales | $ 47 | $ 100 | |||
Actual %, year-on-year | 3% | 17% | |||
CER %, year-on-year | 8% | 20% | |||
Kanuma | US | |||||
Product sales | |||||
Product Sales | $ 25 | $ 47 | |||
Actual %, year-on-year | 21% | 18% | |||
Kanuma | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 5 | $ 19 | |||
Actual %, year-on-year | (54.00%) | 7% | |||
CER %, year-on-year | (49.00%) | 20% | |||
Kanuma | Europe | |||||
Product sales | |||||
Product Sales | $ 15 | $ 30 | |||
Actual %, year-on-year | 28% | 24% | |||
CER %, year-on-year | 33% | 25% | |||
Kanuma | Established ROW | |||||
Product sales | |||||
Product Sales | $ 2 | $ 4 | |||
Actual %, year-on-year | 11% | 11% | |||
CER %, year-on-year | 41% | 20% | |||
Andexxa | |||||
Product sales | |||||
Product Sales | $ 59 | $ 105 | |||
Actual %, year-on-year | 29% | 18% | |||
CER %, year-on-year | 35% | 21% | |||
Andexxa | US | |||||
Product sales | |||||
Product Sales | $ 22 | $ 42 | |||
Actual %, year-on-year | 34% | 14% | |||
Andexxa | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 1 | $ 2 | |||
Andexxa | Europe | |||||
Product sales | |||||
Product Sales | $ 22 | $ 40 | |||
Actual %, year-on-year | 51% | 38% | |||
CER %, year-on-year | 51% | 36% | |||
Andexxa | Established ROW | |||||
Product sales | |||||
Product Sales | $ 14 | $ 21 | |||
Actual %, year-on-year | (6.00%) | (9.00%) | |||
CER %, year-on-year | 8% | 4% | |||
Total Other medicines | |||||
Product sales | |||||
Product Sales | $ 267 | $ 560 | |||
Actual %, year-on-year | (11.00%) | (9.00%) | |||
CER %, year-on-year | (5.00%) | (2.00%) | |||
Total Other medicines | US | |||||
Product sales | |||||
Product Sales | $ 28 | $ 52 | |||
Actual %, year-on-year | (13.00%) | (24.00%) | |||
Total Other medicines | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 179 | $ 385 | |||
Actual %, year-on-year | (3.00%) | (1.00%) | |||
CER %, year-on-year | 5% | 8% | |||
Total Other medicines | Europe | |||||
Product sales | |||||
Product Sales | $ 24 | $ 53 | |||
Actual %, year-on-year | (7.00%) | 10% | |||
CER %, year-on-year | (7.00%) | 10% | |||
Total Other medicines | Established ROW | |||||
Product sales | |||||
Product Sales | $ 36 | $ 70 | |||
Actual %, year-on-year | (38.00%) | (35.00%) | |||
CER %, year-on-year | (32.00%) | (29.00%) | |||
Nexium | |||||
Product sales | |||||
Product Sales | $ 219 | $ 459 | |||
Actual %, year-on-year | (12.00%) | (7.00%) | |||
CER %, year-on-year | (5.00%) | 1% | |||
Nexium | US | |||||
Product sales | |||||
Product Sales | $ 25 | $ 47 | |||
Actual %, year-on-year | (17.00%) | (22.00%) | |||
Nexium | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 146 | $ 318 | |||
Actual %, year-on-year | (2.00%) | 4% | |||
CER %, year-on-year | 7% | 15% | |||
Nexium | Europe | |||||
Product sales | |||||
Product Sales | $ 13 | $ 26 | |||
Actual %, year-on-year | (5.00%) | 3% | |||
CER %, year-on-year | (5.00%) | 2% | |||
Nexium | Established ROW | |||||
Product sales | |||||
Product Sales | $ 35 | $ 68 | |||
Actual %, year-on-year | (37.00%) | (34.00%) | |||
CER %, year-on-year | (32.00%) | (28.00%) | |||
Other, Others | |||||
Product sales | |||||
Product Sales | $ 48 | $ 101 | |||
Actual %, year-on-year | (9.00%) | (17.00%) | |||
CER %, year-on-year | (6.00%) | (14.00%) | |||
Other, Others | US | |||||
Product sales | |||||
Product Sales | $ 3 | $ 5 | |||
Actual %, year-on-year | 39% | (40.00%) | |||
Other, Others | Emerging Markets | |||||
Product sales | |||||
Product Sales | $ 33 | $ 67 | |||
Actual %, year-on-year | (8.00%) | (22.00%) | |||
CER %, year-on-year | (4.00%) | (18.00%) | |||
Other, Others | Europe | |||||
Product sales | |||||
Product Sales | $ 11 | $ 27 | |||
Actual %, year-on-year | (9.00%) | 18% | |||
CER %, year-on-year | (9.00%) | 19% | |||
Other, Others | Established ROW | |||||
Product sales | |||||
Product Sales | $ 1 | $ 2 | |||
Actual %, year-on-year | (54.00%) | (53.00%) | |||
CER %, year-on-year | (49.00%) | (49.00%) | |||
[1] The Q2 2024 and Q2 2023 information in respect of the three months ended 30 June 2024 and 30 June 2023 respectively included in the Interim financial statements have not been reviewed by PricewaterhouseCoopers LLP. |
Alliance Revenue (Details)
Alliance Revenue (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2024 | [1] | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | |
Disclosure of products and services [line items] | |||||
Alliance revenue | $ 482 | $ 341 | $ 939 | $ 627 | |
Enhertu | |||||
Disclosure of products and services [line items] | |||||
Alliance revenue | 683 | 475 | |||
Tezspire | |||||
Disclosure of products and services [line items] | |||||
Alliance revenue | 180 | 105 | |||
Beyfortus | |||||
Disclosure of products and services [line items] | |||||
Alliance revenue | 26 | ||||
Other Alliance Revenue | |||||
Disclosure of products and services [line items] | |||||
Alliance revenue | $ 50 | $ 47 | |||
[1] The Q2 2024 and Q2 2023 information in respect of the three months ended 30 June 2024 and 30 June 2023 respectively included in the Interim financial statements have not been reviewed by PricewaterhouseCoopers LLP. |
Collaboration Revenue (Details)
Collaboration Revenue (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2024 | [1] | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | |
Revenues | |||||
Total collaboration revenue | $ 4 | $ 193 | $ 49 | $ 220 | |
Farxiga: sales milestones | |||||
Revenues | |||||
Total collaboration revenue | $ 49 | 25 | |||
COVID-19 mAbs: licence fees | |||||
Revenues | |||||
Total collaboration revenue | 180 | ||||
Other Collaboration Revenue | |||||
Revenues | |||||
Total collaboration revenue | $ 15 | ||||
[1] The Q2 2024 and Q2 2023 information in respect of the three months ended 30 June 2024 and 30 June 2023 respectively included in the Interim financial statements have not been reviewed by PricewaterhouseCoopers LLP. |
Other operating income and ex_3
Other operating income and expense (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2024 | [1] | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | |
Operating profit, other operating income and expense | |||||
Total other operating income and expense | $ 60 | $ 784 | $ 127 | $ 1,163 | |
Brazikumab licence termination funding | |||||
Operating profit, other operating income and expense | |||||
Total other operating income and expense | 75 | ||||
Divestment of US rights to Pulmicort Flexhaler | |||||
Operating profit, other operating income and expense | |||||
Total other operating income and expense | 241 | ||||
Update to the contractual relationships for Beyfortus (nirsevimab) | |||||
Operating profit, other operating income and expense | |||||
Total other operating income and expense | 712 | ||||
Other | |||||
Operating profit, other operating income and expense | |||||
Total other operating income and expense | $ 127 | $ 135 | |||
[1] The Q2 2024 and Q2 2023 information in respect of the three months ended 30 June 2024 and 30 June 2023 respectively included in the Interim financial statements have not been reviewed by PricewaterhouseCoopers LLP. |